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Abstract 
 
Triple negative breast cancer relapses more frequently than hormone receptor-positive subtypes and is 
often associated with poor outcomes. This is due to the fact that triple negative breast cancer is more 
likely to spread to the brain, where current management strategies do not drastically alter outcomes. 
Protected by the body’s most formidable barrier, the blood brain barrier, treatment options for brain 
metastases is limited and thus prognosis is poor, with survival time measured in months. A promising 
new approach toward by-passing this barrier, is to hijack active transport mechanisms present on the 
endothelial cell membranes, in particular the transferrin receptor. Nucleic acid based aptamers are ideal 
for this purpose given the ability to generate them against a vast range of targets, their stability and 
safety profile. This Thesis aimed to generate a bifunctional aptamer which can transcytose the blood 
brain barrier by targeting the transferrin receptor and specifically delivering a cytotoxic payload to the 
epithelial cell adhesion molecule positive triple negative breast cancer cells. To achieve this a DNA 
transferrin receptor aptamer was truncated to its smallest functional size (Chapter 2), fused with a 
truncated epithelial cell adhesion molecule aptamer to generate a bifunctional aptamer (Chapter 3) and 
loaded with a common chemotherapeutic agent (Chapter 4).  
Chapter 2 describes the truncation of the GS24 transferrin receptor aptamer to 14 nucleotides. Given 
that both the full-length aptamer and the first truncated version possessed an identical loop region, it 
was postulated that this region was the primary binding site. Through introducing mutations into the 
single stranded binding region, an aptamer was generated which demonstrated a superior affinity to 
the transferrin receptor compared to the truncated version of the original aptamer GS24 aptamer.  
Chapter 3 describes the generation of a bifunctional aptamer through the fusion of the truncated 
transferrin receptor aptamer with a truncated aptamer targeting epithelial cell adhesion molecule, a 
membrane glycoprotein overexpression on triple negative breast cancer cells. This generated an 
aptamer with the ability to selectively bind to both targets with a moderate affinity. Furthermore, the 
ability of this aptamer to transcytose the blood brain barrier was confirmed in both an in vitro model 
and a healthy in vivo model. 
Chapter 4 described the functionalisation of the bifunctional aptamer for the treatment of triple 
negative breast cancer brain metastases.  This was achieved through intercalating doxorubicin, a 
common chemotherapeutic used in the treatment of triple negative breast cancer, into the aptamer. 
Following this, the aptamer maintained a moderate affinity toward both targets and was found to be 
 xvi 
 
capable of transcytosing the blood brain barrier in vitro and specifically delivering the cytotoxic payload 
to the epithelial cell adhesion molecule positive triple negative breast cancer cells.  
In conclusion, this Thesis has reported the development of a bifunctional aptamer drug conjugate which 
is capable of transcytosing the blood-brain barrier and delivering a cytotoxic payload to a specific cell 
population.   Further development of the drug-loaded aptamer will facilitate the improvement of 
specific treatments for triple negative breast cancer brain metastases, potentially improve patient 
quality of life and median survival time. Additionally, it serves as a proof of concept for the development 
of targeted drug delivery vehicles for other brain disorders such as glioblastoma or Alzheimer’s disease, 
as the epithelial cell adhesion molecule portion of the aptamer is interchangeable.
 1 
 
Chapter 1: Introduction 
 
Breast Cancer 
Classified as the most common malignant cancer in women worldwide, breast cancer accounts for 25% 
of all cancer cases in women (Brunßen et al., 2016). Developing from normal cells lining the breast 
lobules or ducts, as a result of hereditary or somatic mutations, cancer cells gain the ability to proliferate 
irrepressibly and turn malignant (Lobo et al., 2007). Breast cancer is defined by two categories: in situ or 
invasive carcinoma. Abnormal cell growth beginning and remaining in the site of origin is defined as in 
situ and almost all carcinomas diagnosed at this stage are curable. Compared to this, invasive breast 
carcinomas metastasise to surrounding lymph nodes or other organs throughout the body, thus 
prognosis for these patients is poor (Lobo et al., 2007). In addition to carcinoma type, patient prognosis 
is greatly influenced by disease stage and molecular subtype.  
All types of cancer are subject to a staging system, which define disease extent. Through understanding 
the size of the primary tumour in combination with the extent to which the cancer has spread, clinicians 
are able to establish a clearer prognosis for the patient and design appropriate treatment plans 
(Whitman et al., 2006). The staging system employed for breast cancer revolves around assessing the 
primary tumour, lymph node involvement and metastatic spread (Singletary and Connolly, 2006, 
Whitman et al., 2006). Consisting of five stages (Table 1.1), each with one or more subcategories, this 
system takes into consideration the influential role each characteristic plays in the disease alone and in 
combination with the other characteristics. Stage 0 represents in situ carcinomas, while Stage 1 onwards 
represents invasive carcinomas. Similar to all cancers, the higher the stage of disease the poorer the 
prognosis. This is then further influenced by the fact that breast cancer is a heterogeneous disease 
classified into differing molecular subtypes. 
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Table 1.1: Stages of breast cancer. Table adapted from (Singletary and Connolly, 2006) and (Whitman 
et al., 2006). 
Stage Description 
Stage 0 
In situ carcinomas 
Stage I 
IA 
Tumour is smaller than 2 cm and has not spread to lymph nodes or metastasised  
IB 
No tumour present but lymph nodes have small evidence of cancer 
Tumour is smaller than 2 cm and lymph nodes have small evidence of cancer 
Stage II 
IIA 
Tumour is between 2 and 5 cm and has not spread to lymph nodes 
No tumour present but cancer has spread to less than 4 axillary lymph nodes 
Tumour is 2 cm or smaller and has spread to less than 4 axillary lymph nodes 
IIB 
Tumour is between 2 and 5 cm and has spread to less than 4 axillary lymph nodes 
Tumour is 5 cm or larger but has not spread to axillary lymph nodes 
Stage III 
IIIA 
Tumour is 2 cm or smaller and has spread to 4-9 axillary lymph nodes 
Tumour is larger than 5 cm and lymph nodes have small evidence of cancer 
Tumour is larger than 5 cm and has spread to 1-3 axillary lymph nodes or lymph 
nodes near the breastbone. 
IIIB 
Tumour can be any size and has invaded the chest wall or breast skin and spread 
to up to 9 lymph nodes 
IIIC 
No tumour present or tumour may be any size and cancer has spread to above 10 
lymph nodes 
No tumour present or tumour may be any size and cancer has spread to lymph 
nodes near collarbone 
No tumour present or tumour may be any size and cancer has spread to axillary 
lymph nodes or lymph nodes near the breast bone 
Stage IV 
Tumour of any size with cancerous cells found in the lymph nodes and other 
organs  
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Up until 1990, breast cancer was divided into two molecular subtypes according to the status of 
estrogen receptor (ER) expression, but following extensive gene expression profiling several major 
breast cancer subtypes have been defined (Schnitt, 2010, Ades et al., 2014). Now defined as a 
heterogeneous disease, breast cancer is comprised of four molecularly distinct diseases which have 
unique pathological and biological features, responses to systemic treatments, prognoses and clinical 
behaviours (Ades et al., 2014, Dai et al., 2015). These subtypes include 2 types of ER-positive tumours 
(Luminal A and Luminal B) and two ER-negative tumours (human epidermal growth factor 2 (HER2) 
positive tumours and triple negative tumours).   
Breast cancer molecular subtypes  
The classification of each tumour subtype is determined through the expression of hormonal and 
growth receptors, in combination with proliferation markers. Immunohistochemistry markers classically 
used for subtype classification include ER, progesterone receptor (PR) and human epidermal growth 
factor receptor 2, with each receptor known to mediate cell growth signalling (Dai et al., 2016). 
Proliferation markers are used in the subtyping of breast cancers, including Ki67 and Topoisomerase II 
alpha (TOP2A), to measure proliferation rates. These provide essential information in regards to 
prognosis and the aggressiveness of the disease, both important pieces of information which can be 
utilised to guide the design of treatment regimens and indicate patient prognosis (Beresford et al., 2006).  
Luminal breast cancer  
Defined by the expression of hormone receptors, luminal tumours are the most common molecular 
subtype, accounting for approximately 40 per cent of breast cancers. With similar expression profiles to 
the breast luminal epithelial cells, tumours within this subtype are characterised by the expression of 
hormone receptors and thus are often referred to as hormone positive breast cancer (Dai et al., 2015). 
Given their hormone receptor status, the cells of this subtype depend largely on estrogen and 
progesterone supply for growth and survival (Miller et al., 2014). Determining the expression level of 
these receptors is vital when establishing treatment regimens and plans. This is established through an 
immunohistochemical staining assay carried out on tissue samples from biopsies or tissue removed 
during surgery. At least two further subgroups of this subtype have been identified, luminal A and 
luminal B. While both express ER and PR, they differ in HER2 expression and proliferation rate, with 
luminal B expressing HER2 and having a higher proliferation rate. The prognosis for patients with luminal 
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tumours is generally good, with luminal B having the poorer prognosis of the two subtypes given its 
higher proliferation rate.  
HER2 breast cancer  
Normally expressed at low levels on the epithelial cells of the breast, HER2 is necessary for normal tissue 
development, but in approximately 25% of breast cancers the gene functions incorrectly. HER2 gene 
over-amplification results in overexpression of the HER2 protein, which consequently leads to 
uncontrolled growth and division of breast cells (Dean-Colomb and Esteva, 2008). Classified as a 
member of the ErbB family of receptor tyrosine kinases (RTKs), HER2 receptor activation results in the 
initiation of downstream signalling pathways, which play essential roles in cell proliferation and survival, 
including the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) and the mitogen-activated 
protein kinase (MAPK) pathways (Rexer et al., 2014). The downstream effect of these signalling cascades 
is poorly differentiated HER2 positive tumours, with increased proliferation rates and more frequent 
metastasis, thus resulting in more aggressive tumour behaviour and poor patient prognosis (Dean-
Colomb and Esteva, 2008). Currently, HER2 breast cancer is diagnosed by immunohistochemistry which 
measures HER2 protein levels or HER2 expression via fluorescent in situ hybridisation (FISH), with a 
tumour classified as HER2 positive following an immunohistochemistry score of 3+ or a FISH result of 
more than six HER2 copies/nucleus (Dai et al., 2015, Dean-Colomb and Esteva, 2008).  
Triple negative breast cancer 
Accounting for approximately 15-20% of breast cancers, triple negative breast cancers (TNBC) are 
characterised by their lack of ER and PR receptors and a lack of HER2 overexpression. Defined by their 
highly aggressive nature, triple negative breast cancer tumours occur frequently in younger women and 
have a significantly higher risk of relapse than women with hormone positive breast cancer within the 
first 3 to 5 years following treatment (O’Reilly et al., 2015, Penault-Llorca and Viale, 2012). Testing 
negative for these receptors indicates that the growth of this subtype is not supported by estrogen, 
progesterone or by overexpression of the HER2 receptor. This negative expression then has implications 
for available treatment options as endocrine therapy or HER2 targeted therapy are ineffective.  As a 
result of this, combined with the aggressive nature of this subtype, patients with triple negative breast 
cancer have the worst prognosis of all the molecular subtypes.  
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Treatment strategies for all breast cancer molecular subtypes 
Treatment of breast cancer is largely dependent on the molecular subtype and the stage of the cancer. 
As with most cancers, a multidisciplinary approach is taken for the treatment of breast cancer, with 
surgeons working in close collaboration with the oncologists to achieve the best possible outcome for 
each individual patient (Rostas and Dyess, 2012). Following diagnosis and the establishment of disease 
extent, the patient’s information is reviewed and a treatment management plan is developed. Surgical 
resection plays a critical role in breast cancer treatment and is generally the first step in the 
multidisciplinary approach (Figure 1.1). Depending on the extent of the disease the patient will either 
undergo a partial mastectomy, where the tumour is removed in addition to a small amount of 
surrounding tissue, or a total mastectomy, which involves the complete removal of the breast. Prior to 
this, some patients may undergo a course of neoadjuvant therapy, therapy administered before 
surgery,  to convert an inoperable tumour to an operable one (Schott and Hayes, 2012). Following this 
therapy, a number of patients experience a sufficient tumour response making them eligible for breast 
conserving surgery. However, many patients do not respond or have an insufficient response, leaving 
them with no choice but to undergo a full mastectomy. In addition to the potential clinical benefit of 
neoadjuvant therapy, it also gives an insight into the patient’s response to a particular treatment, which 
may lead to modifications in the treatment protocols following a poor response (Schott and Hayes, 
2012). Following surgical resection, adjuvant systemic therapies and radiation are employed with the 
aim of eradicating micro-metastatic disease which if untreated, could cause tumour recurrence or 
metastatic disease (Figure 1.1). Systemic therapies employed in the neoadjuvant and adjuvant setting 
include cytotoxic and hormonal agents. Given the distinct biomarker profiles of the breast cancer 
subtypes, the choice of adjuvant therapies varies based upon the treatments target and mechanism of 
action.  
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Figure 1.1: Treatment pathway protocol for breast cancer. Prior to undergoing surgical 
intervention some patients receive neoadjuvant chemotherapy to reduce tumour size. Subsequent to 
surgical intervention, adjuvant treatment pathways are highly dictated by molecular subtype, with 
targeted adjuvant treatment options available for hormone receptor positive and HER2 positive 
tumours while treatment of triple negative tumours is limited to chemotherapy. Figure adapted from 
https://wellfollowup.hsnsudbury.ca/breast/Disease-Overview. 
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Luminal subtype systemic treatment 
The main systemic treatment employed in treating luminal tumours is endocrine therapy, which has 
been shown to improve overall survival. As estrogen is the primary stimulant in the growth of these 
tumours, it is a highly attractive treatment target. This has been explored through the development of 
targeted endocrine therapies. Functioning by the manipulation of endocrine signalling pathways, these 
hormone antagonists inhibit estrogen synthesis or biological activity through the arrest of the cell cycle 
in the G1/S phase (Dixon, 2014).  The first endocrine therapy, Tamoxifen, was licensed for the treatment 
of hormone positive breast cancer in 1973 and is considered the standard of care in premenopausal 
patients (Baselga et al., 2009).  Defined as a selective estrogen receptor modulator, Tamoxifen disrupts 
the estrogen signalling pathway by binding to the ER, causing a cascade of events, ultimately leading to 
reduced levels of estrogen regulatedgene transcription (Wakeling, 2000). Treatment with adjuvant 
Tamoxifen over a 5 year period significantly reduces tumour recurrence and mortality rates (Group, 
2005). While very effective in the treatment of pre-menopausal hormone positive tumour patients, 
Tamoxifen is not as effective in post-menopausal patients.  
Aromatase inhibitors are another major group of endocrine therapies which are efficacious in post- 
menopausal hormone positive breast cancer patients. These inhibitors aim to disrupt the estrogen 
signalling pathway  in two ways, the first involves irreversible and inactivating binding to the aromatase 
enzyme (type 1), while the second involves reversible and competitive binding (type 2) (Dixon, 2014, 
Clarke et al., 2015). Through binding to the aromatase enzyme, these inhibitors interrupt the estrogen 
signalling pathway, which reduces estrogen biosynthesis, leading to decreased cell growth and 
proliferation as a result of reduced estrogen levels (Howell and Dowsett, 2004, Miller and Jackson, 2003). 
Currently, there are three aromatase inhibitors employed for the treatment of hormone positive breast 
cancer, Exemestane (type 1), Anastrozole and Letrozole (type 2). When compared to Tamoxifen 
treatment in the adjuvant setting, these inhibitors significantly improve disease free survival, time to 
recurrence and time to distant recurrence in post-menopausal women, however the overall survival 
rates are very similar (Dowsett et al., 2010, Cuzick et al., 2010).  
Endocrine therapy has also been shown to play an important role in neoadjuvant treatment in post-
menopausal women with inoperable tumours. This was demonstrated by The Immediate Preoperative 
Anastrozole or Combined with Tamoxifen (IMPACT) study (Smith et al., 2005). In this phase 3 clinical 
study it was discovered that following 3 months of neoadjuvant Anastrozole treatment, 46% of post-
menopausal women initially deemed ineligible for breast conserving surgery, became eligible (Smith et 
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al., 2005). Similar results were observed in patients who received 6 months of neoadjuvant Exemestane 
therapy (Mustacchi et al., 2009).  While the use of endocrine therapies has significantly reduced the 
number of deaths from hormone positive breast cancers in both pre-menopausal and post-menopausal 
patients, in a number of cases these therapies fail, which can be largely attributed to recurrent 
endocrine-resistant tumours (Dixon, 2014, García-Becerra et al., 2013). As a result of this, the underlying 
cause of this resistance is currently being explored to improve patient response rates.  
HER2-positive systemic treatment 
The overexpression of the HER2 receptor makes it a highly attractive and specific target for the 
treatment of HER2 positive breast cancers. Therefore, treatment regimens revolve around the 
combination of cytotoxic therapy and HER2 targeted therapies. Approved by the FDA in 1997, 
trastuzumab was the first monoclonal antibody developed for the treatment of HER2 over-expressing 
breast cancers and is currently the gold standard treatment. Binding to the extracellular domain IV of 
the HER2 receptor, the molecular mechanisms of trastuzumab can be grouped into three categories: 
MAPK and PI3K/Akt interference, antibody-dependent cellular cytotoxicity (ADCC) and HER2 
degradation (Vu and Claret, 2012). Of these, the most well defined mechanism is the inhibition of the 
MAPK and PI3K/Akt pathway. This is achieved through the disruption of HER2 dimerization, which 
inhibits HER2 activation and suppresses Akt phosphorylation, leading to an increase in cell cycle arrest, 
and reduced cell growth and proliferation (Vu and Claret, 2012, Junttila et al., 2009).  
While sensitive to anthracycline and taxane-based chemotherapeutics, prior to the development of 
HER2 targeted therapies, women with HER2-positve breast cancer faced a poor prognosis and high risk 
of recurrence (Zhang and Liu, 2008). Since FDA approval, trastuzumab treatment in combination with 
adjuvant chemotherapy has significantly improved patient outcomes compared to chemotherapy 
alone. In 2005 Edward et al. presented the combined results of two clinical trials, NSABP B-31 and 
NCCTG N9831, which compared adjuvant chemotherapy with or without trastuzumab following 
surgical removal of HER2-positive breast cancer (Romond  et al., 2005, Perez et al., 2014).  From these 
trials, it was found that the combined treatment significantly reduced mortality rate by one third and 
reduced risk of distant recurrence (Romond  et al., 2005). The definitive overall survival results of these 
studies were then released in 2014, where it was shown that adding trastuzumab to chemotherapy led 
to a 37% improvement in overall survival and an increase in 10-year overall survival rate from 75.2% to 
84% (Perez et al., 2014). Despite improving patient survival, responsive patients develop resistance 
within 1 year of trastuzumab treatment (Nahta and Esteva, 2006, Gajria and Chandarlapaty, 2011). In 
 9 
 
addition to this, not all HER2 over-expressing tumours respond to trastuzumab treatment, therefore 
there is dire need for improved treatment options (Bartsch et al., 2007, Vogel et al., 2002). 
Triple negative subtype systemic treatment 
Due to the absence of the hormone receptors and HER2, there is a lack of targeted therapeutics 
available for patients with TNBC. As a result of this, standard chemotherapy is the mainstay treatment 
and over the past two decades has shown significant benefit in the neoadjuvant, adjuvant and 
metastatic setting (Cortazar et al., 2014, Peto et al., 2012). Of all the breast cancer subtypes, patients 
with TNBC have a higher initial response to chemotherapy than patients with other breast cancer 
subtypes and are particularly sensitive to anthracycline and taxane chemotherapeutics (Anders and 
Carey, 2009, Chacón and Costanzo, 2010).  
Despite being highly responsive to initial chemotherapeutic treatment, TNBC patient prognosis is poor 
compared to the other subtypes. This poor prognosis can be explained by the higher chance of tumour 
recurrence in patients in which pathological complete response (was not achieved. Referred to as the 
triple negative paradox, this observation is supported by a number of neoadjuvant studies (Carey et al., 
2007, Rouzier et al., 2005, Liedtke et al., 2008).  In two separate studies, the initial response of TNBC 
tumours to neoadjuvant chemotherapy and relationship between response and overall outcome were 
investigated (Liedtke et al., 2008, Carey et al., 2007). From both studies, while it was observed that, 
compared to the other subtypes, TNBC patients demonstrated statistically significantly higher pCR rates 
and progression free survival, overall survival rates were significantly inferior (Anders and Carey, 2009, 
Liedtke et al., 2008).  This poor prognosis is the result of indiscriminate chemotherapy being the main 
systemic treatment option and but is largely the result of acquired chemo-resistance.   
Therapy Resistance 
Drug resistance is a major problem in the effective treatment of breast cancer. Despite advances in 
diagnostic techniques and treatment methods, patients still experience tumour recurrence and some 
succumb to the disease. This can largely be attributed to the limited efficacy of chemotherapeutics as a 
result of drug resistance. Divided into two categories, resistance can be defined as pre-existent (intrinsic) 
or drug induced (acquired). Present prior to therapeutic treatment, intrinsic resistance defines the 
presence of resistance-mediating factors in the majority of tumour cells which render therapy 
ineffective (Holohan et al., 2013). Compared to this, acquired resistance is defined by the development 
of resistance in tumours that were originally sensitive throughout the course of treatment (Holohan et 
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al., 2013). This is the result of mutations arising during treatment in combination with adaptive 
evolutionary responses. A diverse range of molecular resistance mechanisms have been identified, 
some of which include drug activation and inactivation, drug efflux, and enhanced DNA damage repair.  
Drug activation and inactivation 
Upon entering the in vivo environment, drug activation involves numerous complex mechanisms. 
Interaction with these mechanisms ultimately leads to drug activation through modifying the drug, 
partially degrading it, or through its combination with other molecules (Housman et al., 2014). Activation 
through these mechanisms is of great importance for some cancer therapeutics which are administered 
in a non-active form and require metabolic activation to acquire clinical efficacy. Given this dependence 
on drug activation, cancer cells can develop resistance to these treatments through decreasing drug 
activation levels (Housman et al., 2014). The activation of cytarabine (AraC), a nucleoside drug used in 
the treatment of acute myelogenous leukaemia, is an example of this (Zahreddine and Borden, 2013). 
Requiring multiple phosphorylation steps for conversion to its active form, AraC-triphosphate, 
downregulation or mutation of enzymes involved in this metabolic pathway leads to reduced drug 
activation, resulting in drug resistance (Sampath et al., 2006, Housman et al., 2014).   
The inactivation of drugs also plays an integral role in the development of resistance. 5-fluorouracil (5-
FU), an antimetabolite chemotherapeutic is widely used in the treatment of colorectal and breast 
cancer. Intracellularly, 5-FU is converted to its active metabolites which disrupt RNA synthesis and the 
action of thymidylate synthase, a nucleotide synthetic enzyme (Longley et al., 2003). Dihyrdropyrimidine 
dehydrogenase (DPD) catabolises 80% of administered 5-FU, primarily in the liver where it is abundantly 
expressed (Diasio and Harris, 1989). Resistance to 5-FU has been demonstrated in vitro in cancer cell 
lines that overexpress DPD (Takebe et al., 2001). Additionally, in colorectal tumours high levels of DPD 
mRNA expression has been correlated with resistance to 5-FU (Salonga et al., 2000). These results 
demonstrate that a higher rate of degradation by DPD leads to the inactivation of 5-FU, as the 
diminished intracellular amounts of the active 5-FU metabolites are incapable of eliciting a relevant 
therapeutic response (Longley et al., 2003).  
Drug efflux 
The efficacy of systemic therapies employed in the treatment of cancer depends upon accumulation 
within cancer cells. The transporter proteins on cancer cell membranes, which promote drug efflux, are 
one of the most studied mediators of drug resistance. This flux across the plasma membrane is regulated 
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by members of the ATP-binding cassette (ABC) transporter family of proteins (Housman et al., 2014). 
Consisting of 49 members in total, each transporter is characterised by a highly-conserved nucleotide 
binding domain and a variable transmembrane domain, though each family member’s structure varies 
from protein to protein (Housman et al., 2014, Chang and Roth, 2001). Upon substrate binding to the 
transmembrane domain, a change in conformation at the nucleotide binding site results in the substrate 
being fluxed out of the cell (Housman et al., 2014). The overexpression of these transporters in cancer 
cell lines and tumours results in multidrug resistance and is one of the major contributors to the failure 
of chemotherapy (Sun et al., 2012). The majority of the research into these transporters and their role 
in chemo-resistance has focused on multi-drug resistance protein 1 (MDR1) and multidrug resistance-
associated protein 1 (MRP1). With each transporter having broad overlapping specificities, these 
transporters eliminate a number of chemotherapeutics employed in the treatment of breast cancer 
(Holohan et al., 2013).   
Multi-drug resistance protein 1 (MDR1) 
MDR1 was the first ABC transporter to be identified in cancer cell lines displaying multi-drug resistance 
(MDR). Expressed in almost all tissues, MDR1 expression is increased as a result of cells turning 
malignant, with high levels of expression generally correlated to expression levels in normal tissues, with 
the tumours of the kidney, liver and colon having the highest levels (Abolhoda et al., 1999, Holohan et 
al., 2013). As a result of this, these tumours are potentially already resistant to cytotoxic agents prior to 
treatment, indicating that MDR1 plays a role in intrinsic resistance (Thomas and Coley, 2003, Holohan 
et al., 2013). In addition to causing intrinsic resistance, it is well established that MDR1 expression can 
increase subsequent to receiving cytotoxic therapy, indicating MDR1 also plays a role in acquired 
resistance (Abolhoda et al., 1999, Housman et al., 2014, Ichihashi and Kitajima, 2001). MDR1 is well 
known for its ability to extrude a wide range of compounds, including structurally unrelated hydrophobic 
anti-cancer drugs, such as paclitaxel, doxorubicin (DOX), vincristine, etoposide and Antimiocyin D, many 
of which are used in the treatment of breast cancer (Table 1.2) (Gottesman et al., 2002, Shukla et al., 
2011, Kuo, 2007). Given its dual role in intrinsic and acquired resistance, in combination with its vast 
range of substrates, overcoming the efflux capacity of MDR1 is vital for the effective treatment of cancer. 
To achieve this, the active development of MDR1 inhibitors (Table 1.2) is ongoing in  order to reverse 
the effects of multi drug resistance in cancer. Developed in the 1980s, Verapamil was the first inhibitor 
developed for MDR1. Promising in vitro analysis of this inhibitor was soon dampened by the occurrence 
of serious cardiac side effects in clinical trials.  As a result, verapamil was deemed an unviable inhibition 
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option (Callaghan et al., 2014, Tsuruo et al., 1982). Following this, over the past 30 years numerous 
generations of MDR1 inhibitors have been produced, but a clinically viable inhibitor is yet to be 
discovered (Pusztai et al., 2005, Ruff et al., 2009, Callaghan et al., 2014). 
Table 1.2: Summary of ABC transporter proteins and their chemotherapeutic substrates and 
therapeutic inhibitors. Table adapted from (Deeken and Loscher, 2007, Loscher and Potschka, 2005, 
Miller, 2010). MDR1, multi-drug resistance protein 1; MRP, multidrug resistance associated protein 1; 
DOX, doxorubicin. 
Transporter Substrates Inhibitors 
MDR1 
DOX, daunorubicin, docetaxel, 
paclitaxel, epirubicin, idarubicin, 
vinblastine, 
vincristine, etoposide 
Verapamil, cyclosporin A, 
quinidine, PSC 833 
(valspodar), GF120918 
(elacridar), VX-710 (biricodar), 
LY335979 (zosuquidar), 
XR9576 (tariquidar) 
MRP1 
Etoposide, teniposide, 
daunorubicin, DOX, 
epirubicin, melphalan, 
vincristine, vinblastine, 5-
fluorouracil  
Probenecid, sulfinpyrazone, 
MK-571, ibrutinib, some P-
glycoprotein inhibitors (e.g., 
cyclosporin A, 
verapamil, PSC 833) 
MRP2 
Similar to MRP1 Probenecid, MK-571, 
leukotriene C4 
MRP3 
Similar to MRP1 Sulfinpyrazone, indomethacin, 
probenecid 
MRP4 
Methotrexate, 6-
mercaptopurine, thioguianine 
Probenecid 
MRP5 6-Mercaptopurine, thioguanine Probenecid, sildenafil 
MRP6 
Actinomycin D, cisplatin, 
daunorubicin, DOX, 
etoposide 
Probenecid, indomethacin 
 
Multi-drug resistance-associated protein 1 (MRP1) 
Identified in 1992, MRP1 was the second drug transport protein identified to play a role in cancer drug 
resistance. While expressed in normal tissues, elevated MRP1 expression levels are consistently seen in 
a variety of different tumours, including breast cancer (Cole, 2014, Deeley et al., 2006). Similar to MDR1, 
MRP1 is characterised by its broad substrate specificity and its overexpression has been correlated with 
chemo resistance to a number of hydrophobic and hydrophilic anti-cancer therapeutics (Table 1.2) 
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employed in the treatment of breast cancer (Cole, 2014). While displaying similar substrate profiles to 
MDR1, MRP1 differs from MDR1 in requiring the presence of co-factors, such as glutathione, glucuronic 
acid or sulfate for the efflux of a number of hydrophobic or cationic drugs (Wind and Holen, 2011, Kuo, 
2007). Given this requirement, these co-factors play an integral role in the regulation of MRP1 activity. 
Glutathione forms conjugates with certain drugs, including platinum based therapeutics, marking them 
as substrates for MRP1 (Wilson et al., 2006, Meijer et al., 1992). While some therapeutics require these 
co-factors, there are a number of therapeutics that alone are substrates, including DOX. Binding of these 
substrates to the transmembrane domain results in a conformational change in the nucleotide binding 
region which pushes them out of the cell. The broad substrate profile of MRP1 makes it a highly 
attractive target to increase chemo-sensitivity and treatment efficacy. Similar to MDR1, inhibitors have 
been developed in an attempt to reduce the efflux capacity of MRP1 and increase drug accumulation 
(Table 1.2) (Tivnan et al., 2015, Zhang et al., 2014). However, to date, none have been successfully 
transitioned into the clinical setting. 
Given that the inhibitors developed so far for MDR1 and MRP1 have been deemed clinically non-viable 
or have not progressed into the clinic, a new direction may need to be taken when designing inhibitors. 
As a result of this, investigation into the role of micro RNAs and chemotherapy response is now being 
explored (Gao et al., 2016, Magee et al., 2015, Zhong et al., 2015). Recently, Gao and colleagues 
published their findings which highlighted the inverse correlation of miR-145 and MRP1 mRNA levels in 
breast cancer (Gao et al., 2016).  Through the administration of miR-145, resistance to DOX in both in 
vitro and in vivo models was reversed through the inhibition of MRP1 (Abolhoda et al., 1999). This 
highlights the potential of miR-145 and other micro RNAs to be explored and developed as MDR 
inhibitors, for increased chemo-sensitivity.  
Enhanced DNA damage repair 
Radiotherapy and various types of chemotherapy agents elicit their cytotoxic effect through directly or 
indirectly causing DNA damage. As a result of this damage, the cell cycle is halted, ultimately leading to 
cell death. If this damage is present in the S phase of the cell cycle it can hinder the replication fork 
progression, resulting in double-strand breaks, which are considered the most toxic form of DNA 
damage (Helleday et al., 2008). Types of damage that play a role in this interference include the chemical 
modification of DNA bases by adducts, which are created through the covalent linkage of drugs to DNA. 
This type of damage is caused by alkylating agents such as cisplatin and temozolomide, which induce 
intra- and inter-strand crosslinks, resulting in a block to replication forks (Helleday et al., 2008, Rodrigues 
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et al., 2013). Anthracyclines, such as DOX, are topoisomerase II inhibitors which also cause double strand 
breaks through intercalating into the DNA or trapping topoisomerase II at DNA breakage sites, resulting 
in cell death following activation of apoptotic pathways (Helleday et al., 2008, Yang et al., 2014).  
The wide spectrum of damage caused by cytotoxic agents is recognised by a range of damage-specific 
repair pathways (Table 1.3). These pathways, often referred to as the DNA damage response (DDR) 
mechanisms, include non-homologous end joining (NHEJ), homologous recombination, base-excision 
repair and nucleotide-excision repair.  The main mechanisms by which double strand breaks caused by 
anti-cancer agents are repaired include homologous recombination and NHEJ (Lord and Ashworth, 
2012). Acting in the S and G2 phases of the cell cycle, homologous recombination restores the DNA 
sequence at the site of damage through copying a DNA sequence on a homologous sister chromatid 
(Lord and Ashworth, 2012, Helleday et al., 2008). Compared to this, NHEJ repairs DNA damage 
throughout the cell cycle by directly ligating the two ends of the break together, regardless of sequence 
homology (Lord and Ashworth, 2012, Helleday et al., 2008). DNA adducts formed by alkylating agents 
can be removed and repaired through base-excision repair or nucleotide excision repair. Base excision 
repair involves the removal of single damaged bases or a short strand containing the damaged bases 
followed by their replacement with newly synthesised DNA. This DDR mechanism repairs small DNA 
adducts whereas some of the bulkier adducts which distort the DNA helical structure are repaired by 
nucleotide excision repair (Lord and Ashworth, 2012). The elevated presence of these repair 
mechanisms within cancer cells can result in the DNA damage being reversed and if this occurs before 
the initiation of replication, the efficiency of the anti-cancer agent is reduced and the cell survives. With 
the ability to effectively reverse the effect of cytotoxic treatment, it is clear that these repair mechanisms 
play a key role in drug resistance and inhibition of these mechanism could enhance the therapeutic 
response of cancer agents. Given that some cells respond to treatment while others are resistant, it is 
has been proposed that a small number of cells within the tumour population are responsible for 
therapy resistance, tumour heterogeneity and tumour initiation.   
 
Table 1.3: Summary of DNA repair pathways involved in repairing DNA damage caused by cancer 
treatments. Table adapted from (Helleday et al., 2008). 
Cancer treatment Toxic lesions Major repair pathways 
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Radiotherapy 
E.g. Ionising radiation 
Single-strand breaks 
Double-strand breaks 
Base damage 
Non-homologous end joining 
Homologous recombination 
Base excision repair 
Antimetabolites 
E.g. 5-Fluorouracil 
Replication lesions 
Base damage 
Base excision repair 
Topoisomerase inhibitors 
E.g. DOX 
Single-strand breaks 
Double-strand breaks 
Replication lesions 
Non-homologous end joining 
Homologous recombination 
Base excision repair 
Nucleotide excision repair 
Alkylators 
E.g. Cisplatin 
Bulky adducts 
DNA cross links 
Double-strand breaks 
Non-homologous end joining 
Homologous recombination 
Base excision repair 
 
Cancer stem cells: their role in tumorigenesis and therapy resistance  
Cancer research for the second half of the last century was based around the idea that each cell within 
a tumour has the ability to form a tumour. Outlined in 1976 by Peter Nowell, within this model it was 
accepted that each cell within a tumour has an equal chance in acquiring random genetic or epigenetic 
mutations thus giving them the ability to generate new tumours (Wang et al., 2013, O'Connor et al., 
2014, Inda et al., 2014). However, there has been great excitement within the research community over 
the past two decades following the idea that tumours possess their own stem cells and are 
heterogeneous populations (Clevers, 2011).  This idea was initially eluded to in the 19th century following 
the discovery of both differentiated and undifferentiated cells in teratocarcinomas, which suggested 
that the undifferentiated cells represented multipotent cancer cells, but did not emerge as a model of 
tumour growth until the 1990s (Nguyen et al., 2012, Jackson and Brues, 1941). Known as the cancer 
stem cell (CSC) model, similar to the growth of normal proliferative tissues, this model proposes that a 
hierarchical organisation of cells exists within a tumour, in which only some cells are responsible for 
tumourigenesis (Figure 1.2) (Clevers, 2011, Visvader and Lindeman, 2012). Analogous to normal tissues, 
three basic functional groups of cells comprise the CSC model of growth: CSCs, progenitor cells, and 
mature tumour cells (Fulawka et al., 2014). Sitting at the top of the hierarchy, the CSCs are a minor 
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population which possess the abilities to self-renew,  differentiate into multiple lineages, and regenerate 
tumours of a similar phenotype (Figure 1.2) (Visvader and Lindeman, 2008, Clevers, 2011). The CSCs 
divide asymmetrically or symmetrically to produce progenitor cells for multi-lineage differentiation and 
daughter cells to preserve the CSC phenotype (Figure 1.2) (Mladinich et al., 2016). Following this division, 
the progenitor cells differentiate into mature tumour cells, which make up the bulk of the tumour 
population. While originally it was proposed that differentiation occurred in a unidirectional manner, it 
is now well established that differentiation is bi-directional, whereby under specific conditions the non-
CSCs de-differentiate into CSCs, thus gaining the ability to self-renew and drive tumorigenesis 
(Prasetyanti and Medema, 2017, Cabrera et al., 2015). This has been defined as the CSC plasticity model. 
The interconversion between non-CSC and CSC states highlights the necessity for combinatorial 
therapeutic approaches to target both populations in order to eliminate the risk of tumour recurrence 
(Singh et al., 2015).  Since the establishment of these tumour growth models, CSCs have been identified 
in a number of different malignancies. 
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Figure 1.2: Schematic overview of the two  CSC models of tumour propagation. In the classical 
CSC model CSCs sit at the top of the cellular hierarchy and generate tumour heterogeneity through 
differentiation into tumour cells which lose the ability to self-renew and proliferate extensively, thus are 
incapable of forming a tumour. Similar to the classical model CSC, in the CSC plasticity model CSCs are 
responsible for driving tumourigenesis but a bi-directional conversion between CSCs and non-CSCs, 
highlighting the necessity for combinatorial therapeutic approaches targeting both populations. Figure 
adapted from (Visvader and Lindeman, 2012, Jordan et al., 2006).  
 
Existence of CSCs 
Despite the initial association of cancer and CSCs in the 19th century, the most conclusive evidence 
supporting their existence was not reported until 1994 (Bonnet and Dick, 1997). This influential work on 
leukemic stem cells, entailed the isolation of a subpopulation of cells expressing CD34+/CD38-, followed 
by transplantation into immunocompromised NOD/SCID mice, which remarkably led to the 
reconstitution of full spectrum acute myeloid leukaemia patient phenotypes (Bonnet and Dick, 1997). 
This functional assay is currently the gold standard for studying and evaluating the ability of a 
subpopulation of human cancer cells to drive tumourigenicity and the pluripotency of CSCs. Alternatives, 
such as the sole identification of CSCs by surface markers, fail to achieve these results. Following this 
momentous discovery, the demonstration of CSCs in solid tumours shortly followed in 2003 when Al-
Hajj and colleagues demonstrated the existence of CSCs in breast cancer (Al-Hajj et al., 2003). Through 
the implantation of as few as 200 CD44+/CD24low/lin– cells in NOD/SCID mice, they demonstrated the 
formation of a phenotypically distinct tumorigenic populations (Al-Hajj et al., 2003). In contrast, the 
implantation of 20,000 cells which did not express these markers were incapable of forming tumours, 
demonstrating that the CD44+/CD24low/lin– population is responsible for tumorigenesis while the 
negative population comprises the bulk of the tumour (Al-Hajj et al., 2003). The existence of CSCs in 
brain tumours was demonstrated in the same year by a number of different groups through the use of 
an in vitro tumour sphere assay followed by cell transplantation into immunocompromised mice (Singh 
et al., 2004, Hemmati et al., 2003, Ignatova et al., 2002, Galli et al., 2004). The subsequent identification 
of CSCs in other solid tumours, including lung, colon and prostate, further supports the theory that 
tumour growth is initiated and maintained by a subpopulation of cells (Collins et al., 2005, O'Brien et al., 
2007). 
Cancer stem cells: the roots of tumour metastasis 
The metastatic cascade highlights the hardiness of cancer cells by their ability to survive harsh 
biochemical processes within the body prior to reaching their metastatic site. While large numbers of 
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cancer cells are released from the primary tumour site into circulation at the beginning of the metastatic 
process, only a small fraction of these cells are able to initiate micro-metastatic growth and an even 
smaller proportion are capable of forming considerable macro-metastases in distant organs (Luo et al., 
2015, Chambers et al., 2002). From this, it is evident that only a specific population of tumour cells are 
capable of forming metastatic lesions, CSCs. (Kucia et al., 2005, Hermann et al., 2007, Clevers, 2011). This 
role of CSCs in the formation of metastatic lesions is supported by the genotypic and phenotypic 
similarities observed between the primary and metastatic tumours (Vanharanta and Massagué, 
Naxerova and Jain, 2015). Discussed previously, it is well established that CSCs have the ability to 
recapitulate the heterogeneous nature of primary tumours following inoculation into 
immunocompromised mice (Bonnet and Dick, 1997). Furthermore, the cellular plasticity of CSCs renders 
them more adaptable to foreign environments different from the primary tumour site (Li et al., 2007).   
Therapeutic strategies to target CSCs 
From a clinical perspective, the presence of CSCs within tumours has serious implications with respect 
to treatment regimens. The presence of these rare tumour initiating cells gives a possible explanation as 
to why current chemotherapeutic treatments often fail.  Sitting at the summit of the hierarchy, CSCs are 
naturally chemo resistant because of their slow growing quiescent state, enhanced DNA repair capacity 
and increased drug efflux transporter expression (Chen et al., 2016). As a result of this, following 
treatment with conventional therapies where the bulk of the tumour is killed, the CSCs remain, 
consequently leading to tumour recurrence and metastatic disease (Figure 1.3). In order to eliminate 
the possibility of disease progression and recurrence, it is essential to develop treatments that possess 
the ability to eliminate both the CSC and non-CSC populations. When developing targeted therapeutics 
for CSCs there are three main challenges to overcome: their quiescent state; small population size; and 
variable location within the tumour. A number of strategies have been explored in an attempt to 
eliminate CSCs, including targeting self-renewal pathways, radio-resistance, quiescence, and the 
targeting of specific CSC surface markers (Al-Hajj et al., 2004, Visvader and Lindeman, 2012). 
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Figure 1.3: Treatment of tumour with conventional therapy. Following treatment with 
traditional therapies the bulk of the tumour population is killed while the CSCs remain. After remaining 
dormant for a period of time the CSCs begin to proliferate resulting in tumour recurrence and, 
potentially, metastatic disease. Figure adapted from (Visvader and Lindeman, 2012) 
 
Targeting CSC signalling pathways 
CSCs share many signalling characteristics with normal stem cells, but disease-specific features within 
these pathways makes them highly attractive treatment targets. Mutation or regulation of the 
Hedgehog (Hh) pathway in adults plays a central role in differentiation and proliferation, leading to 
tumourigenesis or acceleration of tumour growth (Gupta et al., 2010). In both mouse and human 
leukaemia, it was shown that pharmacological inhibition of this pathway repressed the expansion of 
imatinib resistant chronic myeloid leukaemia (CML) (Visvader and Lindeman, 2012, Dierks et al., 2008). 
Similar to the Hh pathway, the Notch signalling pathway is a cell-fate determination pathway which 
influences multiple aspects of cancer biology, including CSCs and angiogenesis (Takebe et al., 2015). 
Inhibition of this pathway through gamma secretase inhibitors or antibodies produces anti-tumour 
effects in a number of different tumours through the induction of cell cycle arrest or apoptosis, or via 
the disruption of angiogenesis (Wei et al., 2010, Weng et al., 2004, Konishi et al., 2007). Furthermore, 
inhibition of the Notch signalling pathway re-sensitizes breast cancer cells to chemotherapeutics and 
enhances their efficacy (Qiu et al., 2013, Zang et al., 2010). While these results are promising and the 
idea of targeting signalling pathways is highly attractive, problems arise when it comes down to 
determining whether treatment methods will additionally affect normal stem cells while treating CSCs. 
Therefore, caution needs to be taken when designing these therapeutics to ensure that only aberrant 
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CSC signalling pathways are targeted to eliminate the risk of side effects being observed on normal 
healthy stem cells.  
Targeting CSC cell surface markers 
While the use of CSC cell surface markers for laboratory studies is an inefficient method for the 
identification of CSCs, their distinct and specific expression enables CSCs to be distinguished from other 
tumour cells and normal stem cells, making them highly suitable for targeted in vivo treatments (Chen 
et al., 2013). To date, numerous cell surface marker proteins have been identified for a range of cancer 
types (Table 1.4).  
First described 30 years ago as an antigen in colon cancer, epithelial cell adhesion molecule (EpCAM), is 
a trans-membrane glycoprotein highly expressed in many types of CSCs (Munz et al., 2009, Shigdar et 
al., 2011a, Soysal et al., 2013).  Following years of research, the role of EpCAM in tumourigenesis has 
been identified. It has been recognised that EpCAM has a direct impact on the cell cycle, ultimately 
leading to the initiation of cell proliferation (Munz et al., 2009). Given its role in proliferation, the 
expression of EpCAM in a number of solid cancer types has been linked to poor patient prognosis 
(Shigdar et al., 2011a, Goossens-Beumer et al., 2014). The overexpression of EpCAM on CSCs in 
comparison to normal epithelia, in combination with its role in tumourigenesis make it an ideal 
therapeutic target. In addition to overexpression, the expression site of EpCAM in cancers cells also 
contributes to its therapeutic potential. While in normal cells EpCAM is expressed on the basolateral 
side of the epithelial membrane, in cancer cells it is expressed preferentially on the apical surface (van 
der Gun et al., 2010). These two differing expression sites further enhance the potential of EpCAM as a 
therapeutic target. As normal cellular EpCAM is less exposed to the environment, such as the 
bloodstream, in comparison to EpCAM on cancer cells, there is great potential to develop targeted 
therapeutics which specifically target cancerous cells, ultimately reducing non-specific side effects.  
Targeting this marker using an anti-EpCAM antibody guided polymer vesicle containing an siRNA 
inhibitor of micro RNA-429, which is known to contribute to hepatocyte malignant proliferation, 
chemoresistance and tumourigenicity, dramatically inhibited EpCAM positive CSCs self-renewable and 
tumour occurring capabilities (Chen et al., 2015). While targeting these cell surface markers is an 
attractive treatment strategy, it is well established that the level and nature of their expression can differ 
between patients and within a tumour itself (Chen et al., 2013). Therefore, in order to develop relevant 
treatment methods capable of attacking the phenotypically different CSCs it is essential to assess 
markers from primary and/or metastatic tumours (O'Connor et al., 2014). 
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Table 1.4:  Cell surface phenotypes of CSCs. Table adapted from (Natarajan et al., 2011, Chen et 
al., 2013)     
Tumour type Phenotype of CSCs Reference 
Breast cancer CD44+CD24-/lowLineage-, ALDH-1high, EpCAM+ 
(Al-Hajj et al., 2003, 
Ginestier et al., 2007, 
Osta et al., 2004) 
Brain cancer CD133+, BCRP1+, A2B5+, SSEA-1+ 
(Singh et al., 2004, 
Gilbert and Ross, 2009) 
Liver Cancer CD133+, CD19f+, CD90+, EpCAM+ 
(Yang et al., 2008, 
Rountree et al., 2008) 
Colon Cancer CD133+, CD44+, CD166+, EpCAM+, CD24+ 
(Dalerba et al., 2007, 
O'Brien et al., 2007, 
Yeung et al., 2010) 
Leukemia 
CD34+CD38–HLA-DR-CD71–CD90–CD117–
CD133+ 
(Bonnet and Dick, 1997) 
 
The metastatic cascade 
The metastatic cascade consists of a series of sequential steps which ultimately leads to the formation 
of metastases at distant sites within the body. The major mechanisms underlying the formation of 
metastatic lesions include the initial dissemination of cancer cells from the tumour via the circulatory 
system, attachment to cells within the vasculature, extravasation into the metastatic site, followed by 
the interaction of the cancer cells with the microenvironment leading to the induction of angiogenesis 
and proliferation (Singh et al., 2014, Preusser et al., 2012). To accomplish this, the cancer cells undergo 
epithelial-mesenchymal-transition (EMT). This transitional process involves the tumour cells undergoing 
inter-conversion between epithelial and mesenchymal states. It is believed migratory characteristics 
acquired during EMT give the cancer cells their invasive capabilities (Tse and Kalluri, 2007). Initially, 
during EMT, cells lose their cell junctions and undergo alterations in signalling programmes that 
increases their motility, enabling them to develop an invasive phenotype and gain access to the 
circulatory system (Lamouille et al., 2014). Upon reaching their metastatic site, the cells then undergo 
mesenchymal-to-epithelial transition (MET), the reverse process of EMT, reverting to the epithelial 
morphology, enabling them to adhere to the metastatic site, and establish a sufficient nutrient supply 
through neo-angiogenesis (Kong et al., 2011).The malignant cells then either remain in a dormant state 
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for a prolonged period of time or continue to proliferate (Fokas et al., 2007). It is these cells, which 
remain dormant, that are responsible for tumour recurrence and metastatic disease, which arises years 
after the treatment of the primary malignancy.  
Metastatic breast cancer 
Defined as the final stage of breast cancer, metastatic breast cancer is the result of primary breast 
tumour cells spreading throughout the body. Through improved diagnostic techniques, breast cancer 
related deaths have decreased. However, approximately 30% of patients diagnosed at early-stage 
disease will develop metastatic lesions and 10% of newly diagnosed patients present with metastatic 
disease (Roché and Vahdat, 2011, Bernard-Marty et al., 2004, Redig and McAllister, 2013). Despite 
treatment advances, the 5 year survival rate for patients with metastatic disease is poor (21%) and 
accounts for 90% of breast cancer related deaths (Bendre et al., 2003, Chen et al., 2014). Often referred 
to as incurable, the treatment options and efficacies of treatments for metastatic breast cancer are 
greatly limited following the development, by the cancer cells, of acquired treatment resistance as a 
result of aggressive cytotoxic regimens (Roché and Vahdat, 2011). Similar to the prognosis and 
treatment options, the metastatic location differs between each molecular subtype, with each subtype 
having a different propensity to metastasise to certain sites within the body (Table 1.5). 
 
 
 
Table 1.5: Frequency of site-specific metastasis among metastatic breast cancer patients 
Table adapted from (Witzel et al., 2016). 
Molecular Subtype Biomarker profile Brain (%) Bone (%) Lung (%) Liver (%) 
Luminal A ER+PR+HER2- 8-15 65-67 6-7 12-29 
Luminal B ER+PR+HER+ 11 58-71 24-30 4-32 
HER2-positive ER-PR-HER2+ 11-20 61-62 15-42 22-44 
TNBC ER-PR-HER2- 25-27 17-39 40-43 13-21 
 
 23 
 
Breast cancer brain metastases 
Second to lung cancer, breast cancer is the second most frequent cancer to metastasise to the brain, 
with 15-30% of patient suffering from metastasis (Leone and Leone, 2015, Witzel et al., 2016).  Prognosis 
for breast cancer patients who have developed metastatic brain tumours is affected by a number of 
factors, including tumour subtype, time of diagnosis and number of metastatic lesions. Even with 
neurosurgery and radiotherapy, survival rates are poor, with few patients living longer than a year 
(Quigley et al., 2013, Witzel et al., 2016). Highlighted in Table 1.5, of the four breast cancer subtypes, 
TNBC has the highest frequency of metastasis to the brain. Similar to the primary tumour setting, given 
the lack of targeted therapies available for the treatment of TNBC tumours, patient prognosis is poor. In 
2014, in a retrospective study of 1256 patients diagnosed with brain metastases conducted by Niikura 
et al., it was shown that patients with HER-2 positive tumours had an overall average survival of 16.3 
months, compared to those with luminal tumours, who had an overall average survival of 9.3 months, 
while patients with TNBC tumours had a mere average survival of only 4.9 months (Niikura et al., 2014). 
These options are then further reduced by the fact that these tumours are located within the control 
centre of the human body and great caution must be taken.   
Treatment of TNBC brain metastases 
The main objective when treating TNBC brain metastases is to maximise the patient’s survival and 
functional state, without compromising neurological status. To achieve this, treatment protocols are 
based around multiple factors, including age, health status, systemic disease burden, number of lesions 
and their location (Hardesty and Nakaji, 2016). Taking these factors into account, treatment generally 
revolves around a multi-modality strategy utilising a combination of treatment options, including 
surgical resection, whole brain radiation therapy (WBRT), stereotactic radiotherapy (SRS) and traditional 
chemotherapy.  
Dependent upon the number of metastatic tumours, the first typical treatment step is surgical resection. 
This treatment option has multiple associated benefits, including the immediate elimination of life 
threatening effects such as intracranial pressure and focal deficits (Leone and Leone, 2015). Resection 
of the tumour mass also allows for histological confirmation, which may be beneficial when choosing 
other treatment options. In addition to providing symptom relief, surgical resection can also provide 
survival benefit. The role of surgical resection in patients with single brain metastasis was first 
investigated in the 1980s and further validated in the early 1990s by two randomised clinical trials 
(Sundaresan and Galicich, 1985, Patchell  et al., 1990, Vecht et al., 1993). The first trial conducted by 
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Patchell and colleagues investigated the effect of surgical resection followed by WBRT or WBRT alone in 
48 randomly assigned patients suffering from single brain metastasis and absent or controlled systemic 
disease (Patchell  et al., 1990). Patient survival in the surgical resection group was found to be 
significantly longer than that of the WBRT alone group (40 weeks vs 15 weeks, p< 0.01). In a similar study 
three years later, a comparable result was observed with patients receiving surgery and WBRT surviving 
four months longer than those treated with WBRT alone (Vecht et al., 1993).  These results have been 
further supported by non-randomised studies in which survival rates and neurological outcomes were 
improved by the combined treatment of surgical resection and WBRT (Rades et al., 2008, Ampil et al., 
1996). Though surgical resection has been shown to improve survival in patients with single brain 
metastasis and controlled systemic disease, there is little evidence supporting its benefit in patients with 
more than 4 lesions and active or uncontrolled systemic disease (Hatiboglu et al., 2013).  
WBRT is an important treatment option for patients suffering from brain metastases. Up until the 1950s, 
supportive care was the only viable treatment option available for metastatic brain tumour patients. 
Following the release of a publication on the use of various doses of external radiation for the 
therapeutic relief of symptomatic metastases, the foundation for WBRT being used in treatment of 
brain metastases was set (Chao et al., 1954, McTyre et al., 2013). Designed to treat multiple metastases 
and eliminate micro metastases, WBRT involves the delivery of radiation to the entire brain through 
daily treatment (Smart et al., 2015). Through its introduction into treatment regimens, WBRT improved 
survival rates from 1-2 months to 4-6 months and as a result became a standard treatment (Halasz et 
al., 2016). The results from the clinical trials involving WBRT as an adjuvant therapy to surgical resection 
demonstrates that it plays a pivotal role in improving patient’s survival (McPherson et al., 2010, Patchell  
et al., 1990). While advanced treatment options for single metastatic lesions has seen the use of WBRT 
reduced, it still plays an essential role in the treatment of patients with multiple metastases and 
uncontrolled systemic disease. As WBRT entails irradiating the entire brain, there are a number of 
associated side effects and limitations. These include hair loss, headache, serous otitis media, and 
neurocognitive dysfunction (McTyre et al., 2013). Though cognitive dysfunction may be considered the 
most detrimental side effect of WBRT in long term survivors, it is important to note that tumour 
progression can have a similar, if not more adverse effect than WBRT. Thus, more research is required 
to enhance the efficacy of this treatment and to limit the associated side effects.   
Stereotactic radiosurgery (SRS) is a form of radiation therapy used for the treatment of small metastatic 
lesions. With technological advancement, SRS has become an alternative treatment for patients with 
limited disease and deemed poor candidates for surgical resection or whose lesions are located in 
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anatomically difficult positions (Leone and Leone, 2015). Compared to WBRT, which involves radiating 
the entire brain, SRS delivers high doses of radiation focally to tumour sites, minimising radiation 
necrosis on surrounding tissues (Ahluwalia et al., 2014).  The fact that this treatment is also performed 
on an outpatient basis and does not require anaesthesia, are additional advantages. The efficacy of this 
treatment has been reported in numerous studies, with the majority exploring the benefit of combining 
SRS with WBRT compared to WBRT alone. In a large retrospective multi-institutional analysis conducted 
in 2001 by Sanghavi and colleagues, where patients with single brain metastasis were stratified by 
recruiting portioning analysis (RPA) class, the combined treatment of SRS and WBRT significantly 
improved median survival time in all classes compared to WBRT alone (Sanghavi et al., 2001). Results 
from a randomised control phase III trial (RTOG 9508) published in 2004 demonstrated similar results, 
with patients suffering from a single lesion having a significantly increased median survival time 
following combined treatment compared to WBRT alone (6.5 months vs 4.9 months) (Andrews et al., 
2004).  Patients within this study suffering from multiple metastases did not experience improved 
median survival rates, though local control was significantly improved. These findings have been seen in 
a number of phase III trials (Chang et al., 2009, Aoyama et al., 2006, Kocher et al., 2011). The role of SRS 
alone for the treatment of one metastatic lesion has been investigated, with mixed results being 
reported. In a retrospective study of 236 patients conducted between 1984 and 1997, Pirzkall et al. 
reported that compared to SRS plus WBRT, SRS alone resulted in no significant difference in median 
survival (Pirzkall et al., 1998). Compared to this, in a recently published article utilising the National 
Comprehensive Cancer Network (NCCN) Oncology Outcomes Database, Halasz et al. reported improved 
survival among patients with fewer than four brain metastases treated with SRS versus WBRT (Halasz 
et al., 2016). While survival rates can be improved through the implementation of SRS into therapeutic 
regiments, this treatment method results in similar side effects to those associated with WBRT. In 
addition to these side effects, while both treatments can improve median survival rates, these 
improvements are merely measured in months. Therefore, there is a dire need to either improve the 
effectiveness of these treatments or develop alternative therapeutic options with the ability to 
specifically target the metastatic lesions to limit side effects, in addition to improving survival rates by 
years rather than months.  
Currently, there is no standard chemotherapeutic agent routinely used for the treatment of TNBC brain 
metastases. Similar to the primary tumour, due to the absence of the hormone receptors, there is a lack 
of targeted therapeutics available for TNBC brain metastases, leaving chemotherapy as the only 
systemic treatment option (Leone and Leone, 2015). Initial studies using traditional chemotherapy 
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combinations, including cyclophosphamide, cisplatin, etoposide and 5-fluorouracail, have shown 
objective response rates of up to 50% in patients with breast cancer brain metastases (Leone and Leone, 
2015, Rosner et al., 1986). A similar response rate was observed (40%) when temozolomide, the gold 
standard therapeutic agent used for the treatment of primary brain tumours, was combined with 
cisplatin (Christodoulou et al., 2005). These poor response rates to some extent can be explained by the 
presence of the blood brain barrier (BBB), a highly restrictive barrier which limits the movement of 98% 
of small molecules from entering the brain and disrupting homeostasis (Gabathuler, 2010).  An 
important factor to consider is that while these chemotherapeutic agents differ in their ability to traverse 
the BBB, during metastatic invasion this barrier is disrupted, allowing impenetrable drugs to cross into 
the brain microenvironment. While this initially results in the treatment of the metastatic lesion, the BBB 
is eventually repaired. The presence of an intact BBB greatly reduces treatment options and results in 
the presence of potentially chemo resistant cancer cells being protected by the BBB, ultimately leading 
to the possible development of multiple metastatic lesions.  
Influence of the blood-brain-barrier on the treatment of TNBC brain 
metastases 
The human brain requires a precise microenvironment in order to function optimally. This environment 
is provided and maintained through the defined function of the BBB. This highly impermeable barrier 
plays a key role in brain homeostasis by segregating the brain from the blood impeding the influx of 
blood-borne molecules (Ballabh et al., 2004, Abbott et al., 2010). As a result of this restrictive barrier, the 
availability of systemic treatments for brain metastases is greatly reduced compared with the available 
treatments for other tissues. 
Structure and the function of the BBB 
Present at all levels of the vascular tree, the BBB is composed of endothelial cells lining the brain 
vasculature coupled with surrounding astrocytes and pericytes (Figure 1.4). Forming the morphological 
basis of the BBB, brain endothelial cells are phenotypically dissimilar to those of the peripheral 
circulation (Bernacki et al., 2008). Brain endothelial cells are characterised by their highly polarised tight 
junctions connecting them to adjacent cells. This junction, in combination with a lack of pinocytic 
vacuoles, limits the free transport of molecules into the brain (Deeken and Loscher, 2007, Daneman, 
2012). While not directly involved in transport limitation, both astrocytes and pericytes play supportive 
roles towards the endothelial cells and maintenance of the BBB.  Astrocytes play essential roles in 
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neuronal metabolism, nutrition, and waste removal, while pericytes are complex regulatory cells that 
communicate with other cells of the BBB, regulating endothelial cell activity (Bernacki et al., 2008, Dore-
Duffy, 2008).  
 
Figure 1.4: Cellular associations of the BBB. The BBB consists of a polarised layer of endothelial 
cells joined together through tight junctions which are lined by surrounding astrocytes.  Figure adapted 
from (Abbott et al., 2010). 
 
In addition to the cellular components that comprise the BBB, non-cellular components exist, which 
provide structural support. Comprised largely of structural proteins, the basement membrane is an 
essential part of the BBB which covers the endothelial cells from the outside (Wilhelm et al., 2013). 
Surrounding and anchoring the cellular components in place, this membrane is created by 3 apposed 
laminas, each of which are composed of different extracellular matrix molecules (Cardoso et al., 2010). 
These include collagen, elastin, fibronectin, laminin and proteoglycans (Cardoso et al., 2010, Mäe et al., 
2011). The association of this membrane and the cellular components is one of mutual benefit, with the 
membrane providing structural support while the endothelial cells, pericytes and astrocytes work 
together to generate and maintain the membrane (Cardoso et al., 2010).  
The junctional complexes present between adjacent endothelial cells of the brain microvessels are the 
most important factors responsible for the impermeable nature of the BBB (Bernacki et al., 2008). There 
are two main types of junctional complexes present between the endothelial cells, tight (TJ) and 
adheren junctions (AJ), that together determine the overall paracellular permeability of the BBB. 
Composed of an intricate balance of cytoplasmic and transmembrane proteins linked to an actin 
cytoskeleton, the TJs of the BBB create a rate-limiting barrier to paracellular diffusion of solutes (Huber 
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et al., 2001). Structurally, these junctional complexes form a series of multiple barriers being formed of 
a continuous network of intramembrane strands of parallel proteins (Figure 1.5) (Huber et al., 2001, 
Luissint et al., 2012). Three key integral proteins constitute the transmembrane component of these TJs, 
occludin, claudin and junctional adhesion molecules (JAMs). Together, these proteins create the primary 
seal of TJs through the formation of dimers and connection to their counterpart on adjacent endothelial 
cells (Huber et al., 2001, Luissint et al., 2012).  While these transmembrane proteins are essential for TJ 
composition and function, several additional cytoplasmic proteins are required for the full function of 
the complexes. Numerous accessory proteins are crucial in providing structural support for TJs. Of these, 
zonula occluden (ZO) proteins are of the most importance. Linked to the cytoplasmic C-terminal of both 
claudin and occludin, ZO proteins link these transmembrane proteins to an actin skeleton, providing 
structural and functional integrity to the endothelium (Abbott et al., 2010).  While the TJs of the BBB 
limit the diffusion of solutes, AJs provide structural support, holding adjacent endothelial cells together 
(Figure 1.5). Spanning the intercellular cleft between endothelial cells, cadherin proteins bridge 
neighbouring endothelial plasma membranes via their homophilic interactions (Meng and Takeichi, 
2009, Huber et al., 2001). Similar to TJs, cytoplasmic catenin proteins play an analogous role to ZO 
proteins, intracellularly linking cadherins to the cytoskeleton (Huber et al., 2001, Gloor et al., 2001).  
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Figure 1.5: Junctional complexes of the BBB tight junctions. The BBB consists of a physical and 
physiological barrier whereby the physical component is comprised of TJs and AJs, that together restrict 
the movement of molecules from the blood to the brain. Generated through three integral 
transmembrane proteins, occludin, claudin and junctional adhesion molecules, interconnected with 
accessory proteins, TJs limit the paracellular diffusion of solutes.  AJs provide structural support for the 
BBB through holding adjacent endothelial cells together.  Figure adapted from (Abbott, 2013),(Tosoni 
et al., 2004).    
 
Transport systems of the BBB 
The highly polarised nature of the BBB endothelial cells generated by the proteins present within the TJs 
produces unique membrane compositions. This, in conjunction with the overall tightness of the 
structure, restricts the transport of molecules greater than 500 daltons (D) into the brain (Daneman, 
2012). This results in the prevention of an overwhelming majority, reportedly 98%, of small molecules 
from crossing the BBB (Gabathuler, 2010). In addition to this, the few drugs capable of crossing the 
barriers are actively pumped back out by protein efflux transporters present on the endothelial cells 
membranes.  The overall restrictive nature of this barrier impedes the delivery of vital nutrients, minerals 
and molecules essential for the maintenance of brain homeostasis. Though the restrictive architecture 
of the BBB impedes the influx of hydrophilic substances essential for the maintenance of brain 
homeostasis from the blood to the brain, the presence of carrier and receptor mediated transport 
systems (Figure 1.6) promotes the transportation of molecules essential for cerebral function (Svetlana 
et al., 2011).  
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Figure 1.6: Mechanisms of transport across the BBB. A number of transport processes can be 
distinguished: (A) Passive diffusion, a mechanism driven by a concentration gradient mainly involving 
small hydrophobic molecules. (B) ABC Transporter efflux, transporters which play a critical role in 
preventing neurotoxic substances from entering the brain. (C) Carrier mediated transport, transport 
mechanisms of many essential polar molecules. (D) Receptor mediated transcytosis, requires receptor 
binding of ligand and can transport a variety of macromolecules (E) Adsorptive transcytosis, a non-
specific transport mechanism dependant on charge. (F) Paracellular aqueous pathway, transport limited 
to water soluble molecules. Figure adapted from (Gabathuler, 2010),(Abbott, 2002).    
 
ABC transporter efflux 
The protective role of the BBB is further enhanced by efflux transporter proteins. Present on the 
abluminal and luminal sides of the endothelial cells, which line the brain microvasculature, these 
transporters have a dual role, firstly to protect the brain microenvironment from the influx of 
neurotoxins and secondly, restrict the access of therapeutic modalities to the brain (Figure 1.6B).  (Miller, 
2010). Identified as playing a key role in the chemo-resistance of cancer cells, these efflux pumps have a 
similar effect in the endothelial cells of the BBB. Their presence has significant implications on the 
systemic treatment options available for patients suffering from brain metastases, as they efficiently 
remove drugs before a therapeutically relevant dose can be achieved. This is evident in the case of lipid-
soluble drugs which would be expected to easily diffuse across the BBB but due to these transporters, 
have lower permeability than that predicted by their lipid solubility (Deeken and Loscher, 2007).  
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Numerous efflux transporters have been identified on the BBB endothelium, including MDR1, multidrug 
resistance proteins and organic anion and cation transporters (Deeken and Loscher, 2007, Cioni et al., 
2012).  
Transport proteins 
The highly restrictive nature of the BBB results in the majority of small polar molecules being incapable 
of diffusing into the brain (Figure 1.6C). These molecules include glucose, amino acids, nucleosides and 
many other molecules. Given the essential roles these molecules play in cell growth and metabolism, it 
is therefore essential for them to be transported across the BBB. This is achieved through the presence 
of carrier mediated transport proteins present on both the luminal and abluminal membranes of the 
endothelial cells of the BBB. These proteins mediate the bi-directional movement of these molecules 
between the blood and the brain.  Examples of these transporters, include the GLUT1 glucose 
transporters, LAT1 large neutral amino-acid transporters and CNT2 concentrative nucleotide adenosine 
transporters. 
Receptor mediated transcytosis 
Transcytosis across the BBB via endocytic mechanisms is the main route by which large macromolecules 
enter the brain microenvironment (Figure 1.6D). In this mechanism, following ligand binding to the 
receptor on the apical membrane, the membrane invaginates this complex forming an intracellular 
vesicle, where it is shuttled to the basolateral membrane and the contents of the vesicle are released 
(Lajoie and Shusta, 2015). The best example of receptor-mediated transcytosis (RMT) operating in the 
BBB is the transport of iron loaded transferrin (Tf). Playing an essential role in mitochondrial energy 
generation, neurotransmission, oxygen transport, and cellular division, the transport of iron into the 
brain microenvironment is critical for normal brain function (McCarthy and Kosman, 2015, Ponka and 
Lok, 1999). Upon association with the transferrin receptor (TfR) at the apical endothelial cell surface, the 
iron-bound Tf is internalised and following a drop in pH (pH 7.4 to 6.0), iron is released into the early 
endosome, where it is then released into the brain following the fusion of the vesicle with the basolateral 
membrane (Georgieva et al., 2014, Ponka and Lok, 1999).  
Methods to overcome the BBB 
Given the significant need to increase cytotoxic therapy accumulation in metastatic brain tumours, 
numerous strategies to enhance delivery have been investigated. These approaches generally follow a 
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number of strategies, including bypassing the BBB through local delivery of therapeutic agents, the 
delivery of chemotherapeutics simultaneously with drug transport inhibitors, disruption of the barrier, 
and hijacking receptor mediated transport mechanisms present on the BBB endothelium.  
Bypassing the BBB 
An approach to deliver therapeutically relevant concentrations of chemotherapeutic agents into the 
brain is through bypassing the BBB by direct administration. This method of administration enables 
chemotherapeutic agents to avoid the formidable obstacles faced by systemic delivery.  Delivery in this 
manner is achieved through intrathecal delivery, which involves administration of chemotherapeutic 
agents into the lumbar subarachnoid space (Hersh et al., 2016). In contrast to systemic administration, 
where the entire body is subjected to the cytotoxic agent, intrathecal administration is specifically 
administered to the brain and requires a significantly lower dose to achieve a high drug concentration 
(Hersh et al., 2016). While this method of administration involves administering a lower dose of the 
cytotoxic agent, there are a number of associated disadvantages. These include the highly invasive 
nature of the method, non-targeted drug distribution, non-homogeneous dispersion, and the 
ineffective volume of drug distribution (Wu et al., 2014). Of these limitations, the most important is the 
non-targeted drug distribution. Given the indiscriminate nature of current chemotherapeutics, their 
direct administration into the brain microenvironment could result in a significant amount of neurotoxic 
and cognitive damage. Therefore, given the detrimental side effects associated with this treatment, non-
invasive treatment options are more favourable.  
Inhibition of drug efflux transporters 
One method to increase drug concentration in the brain is through the inhibition of drug efflux 
transporters present on the BBB endothelium. Over the past two decades, extensive research has been 
undertaken to develop agents capable of inhibiting these transporters at the cellular level (Deeken and 
Loscher, 2007). The most extensively studied efflux transporter of the BBB is MDR1, given its high 
expression on the luminal surface of the endothelial cells, which comprise the barrier. Using in vivo 
animal models, the administration of MDR1 inhibitors were shown to increase the intracranial 
concentration of a number of chemotherapeutic agents, including paclitaxel and vinblastine (Fellner et 
al., 2002, Cisternino et al., 2001). In mice, with a xenograft orthotopic glioblastoma tumour treated with 
the inhibitor PSC-833 and paclitaxel, increased concentrations of paclitaxel were recorded in the brain 
and improved tumour response was observed compared to animals treated with paclitaxel alone 
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(Fellner et al., 2002).  Similar results were observed following the administration of vinblastine with the 
inhibitors PSC-833 and GF 120918 (Cisternino et al., 2001). Despite promising in vivo results, testing of 
MDR1 inhibitors in clinical trials is limited. Therefore, further evaluation of MDR1 inhibition at the BBB 
to increase drug accumulation in the brain is required.  
Disrupting the BBB  
BBB disruption has been investigated for transiently disrupting the BBB to increase permeability and 
thus uptake of therapeutic agents. This disruption can be achieved through three mechanisms, osmotic 
or chemical disruption, or by focused ultrasound. Hyperosmotic disruption has been explored since the 
1970s and is still being tested in clinical trials today as a method for increasing chemotherapeutic uptake 
(Hersh et al., 2016, Chakraborty et al., 2016). This method works on the principle of osmosis, where 
hypertonic solutions are injected into the patient, causing the endothelial cells to shrink following the 
net movement of water into the blood vessel lumen. This net flow of water out of the brain then leads 
to vasodilation which stretches the endothelial cell membranes. This cascade of effects places significant 
stress on the tight junctions causing them to disrupt and widen, allowing paracellular diffusion into the 
brain parenchyma to occur (Oberoi et al., 2016, Hersh et al., 2016). Mannitol is the most commonly used 
hyperosmotic agent for osmotic BBB disruption. Utilising this method, pre-clinical studies have 
demonstrated that following osmotic barrier disruption using mannitol, the concentration of intra-
arterially delivered chemotherapeutics in the brain can be substantially increased (Neuwelt et al., 1980). 
However, while this method is safe for some chemotherapeutics it is not safe for all, with some agents 
reaching neurotoxic levels following barrier disruption (Neuwelt et al., 1983). Since this pre-clinical trial, 
numerous clinical trials and studies have taken place. In paediatric patients with non-glial primary brain 
tumours or embryonal and certain germ cell tumours, it was found that following osmotic barrier 
disruption, methotrexate and carboplatin could be delivered into the brain (Dahlborg et al., 1998, Jahnke 
et al., 2008). Regardless of these promising results, the implementation of osmotic barrier disruption in 
the clinical setting has not yet occurred. This can be attributed to the associated side effects with this 
method, including the lack of specificity, the associated neurotoxicity, and effects on blood pressure and 
fluid balance (Hersh et al., 2016). The major limitation of this method is that barrier disruption is global, 
meaning it non-selectively disrupts the entire barrier. This in turn results in blood-borne substances 
incapable of crossing the barrier gaining access, which can result in adverse effects such as seizures and 
neurological damage (Kemper et al., 2004). This significant limitation highlights the need for a barrier 
disruption method that specially disrupts the BBB at brain tumour sites.  
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Specific disruption of the BBB in the same region as brain tumours has been achieved through chemical 
disruption. In paediatric brain tumour patients, Bradykinin, a vasoactive substance has been used to 
selectively disrupt and open the BBB without affecting tumour free sites (Elliott et al., 1996). Through 
increasing cytosolic calcium ions following binding to B2 receptors on endothelial cells, Bradykinin 
activates nitric oxide synthase, an enzyme prevalent in tumour vasculature (Hersh et al., 2016). This 
produces an increase in nitric oxide, which results in vasodilation and increased vascular permeability 
(Matsukado et al., 1998). Given its higher potency, greater specificity and resistance to degradation, an 
analogue of Bradykinin, RMP-7, has become more commonly used in clinical studies for chemical barrier 
disruption (Emerich et al., 2001). Promising early clinical results found that through the use of RMP-7, 
uptake of carboplatin was increased, resulting in tumour shrinkage (Warren et al., 2001, Cloughesy et 
al., 1999, Gregor et al., 1999). However, when this combination therapy moved forward to a placebo-
controlled trial, the pre-clinical results could not be replicated and the combination was deemed 
ineffective (Prados et al., 2003). While there have been some promising results using this barrier 
disruption method, as with osmotic disruption there are a number of associated side effects and 
limitations, including the highly invasive administration method and high levels of toxicity (Ford et al., 
1998). While this method of disruption addressed the limitation of specificity associated with osmotic 
disruption, it is a highly invasive procedure and this limitation needs to be addressed.  
Focused ultrasound (FUS) is a non-invasive method where ultrasound is used to transiently disrupt and 
open the BBB. While the concept of using ultrasound for disruption was conceived in the 1950s, the 
development of this therapy lapsed as a result of its limitations, including beam distortion and 
attenuation produced by the skull (Ballantine et al., 1960). As a result of this, a window in the skull was 
required to focus the beam through, thereby turning a potentially non-invasive method into an invasive 
one. In the 1990s, through technological development, this critical limitation was overcome and the 
procedure was capable of being administered through an intact skull (Hynynen and Jolesz, 1998). The 
permanent tissue damage associated with this method was minimised through lowering the frequency 
threshold through incorporating intravenously administered lipid-encased perfluorocarbon gas 
microbubbles (Etame et al., 2012). The principle behind this is that when the microbubbles pass through 
the ultrasound field directed to the tumour site, they oscillate at the same frequency as the ultrasound 
beam, causing them to expand and contract. The change in size between these contractions and 
expansions causes mechanical stimulation of the blood vessels, which in turn causes the BBB to open 
(Burgess et al., 2015). The effect of FUS in improving the uptake of DOX in mouse and rat models of 
glioblastoma has been explored over the past decade (Park et al., 2017, Kovacs et al., 2014, Treat et al., 
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2012, Treat et al., 2007). While these in vivo models have shown increased concentrations of DOX within 
the brain and tumour, in addition to significantly improved survival, they did not present any data in 
relation to the whole-body bio-distribution of DOX. As with all chemotherapeutic agents, DOX works in 
an indiscriminate manner, therefore while the concentration in the brain increases with FUS, it may still 
be toxic to non-diseased cells throughout the body and the brain. This method would therefore be more 
suited for the increased delivery of targeted agents.  
The delivery of target specific antibodies using FUS has been explored in HER2-positive brain metastases. 
It is well documented that the HER2-targeting antibodies trastuzumab and pertuzumab improve 
survival in patients with HER2-positive extracranial metastases (Swain et al., 2015).  However, given the 
inability of these treatments to cross the BBB, the incidence of HER2-positive intracranial metastases 
has increased. Treatment options for HER2-positive brain metastases are therefore limited. The 
feasibility of using FUS to overcome this barrier and improve delivery has been investigated in vivo 
(Kobus et al., 2016, Kinoshita et al., 2006, Park et al., 2012).  From the study conducted by Park and 
colleagues, it was observed that FUS plus trastuzumab treatment significantly improved patient survival 
compared to trastuzumab alone (Park et al., 2012).  The result of most importance from this study is the 
fact that a response to treatment was only observed in some of the animals. Park and colleagues could 
not identify an obvious reason for this observation but alluded to the possibility of a difference in 
vasculature to be a potential cause (Park et al., 2012). Given that vessels with a small diameter (20-30 
µm) have faster leakage and permeability compared to larger vessels (~40-60 µm), this could be a 
possible explanation for the different responses to FUS between treatment groups (Park et al., 2012).  
Since 2012, this response rate has been consistently observed in subsequent studies (Alkins et al., 2016, 
Kobus et al., 2016). While the use of FUS has been explored in HER2-positive breast cancer, given the 
current lack of targeted treatment options for TNBC and the indiscriminate nature of 
chemotherapeutics, at present FUS is not presently a feasible treatment method for TNBC brain 
metastases.  
Hijacking transport mechanisms 
A promising technique being developed to deliver chemotherapeutics and treat brain malignancies is 
the development of therapeutic modalities which are substrates for influx transporters present on 
endothelial cell membranes. Through designing drugs and transport modalities for these transporters 
they attain the ability to pass through the BBB without disruption, in addition to circumventing the efflux 
capacity of the BBB, ultimately increasing drug delivery to brain tumours (Deeken and Loscher, 2007).  
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Given the strong expression of the TfR on the BBB, numerous therapeutics have been generated in an 
attempt to improve the therapeutic treatment of Alzheimer’s disease and glioblastoma (Xu et al., 2011, 
Wilner et al., 2012, Yu et al., 2011). In 2011, Xu et al. reported the anti-tumour effects of an anti-Tf 
monoclonal antibody on glioma cells in vitro, both in combination with a chemotherapeutic drug and 
alone (Xu et al., 2011). Interestingly, results from this study showed that the antibody alone had an anti-
proliferative effect through induced S phase accumulation and apoptosis, and when used in 
combination with the chemotherapeutic the effect was further enhanced, which suggested that 
combination therapy was more effective (Xu et al., 2011). In the same year, Yu et al. reported the 
development of a bi-specific antibody capable of exploiting the TfR and targeting an enzyme associated 
with Alzheimer’s disease (Yu et al., 2011). The reduction in amyloid-β production following antibody 
administration, demonstrates that, through targeting the TfR pathway, a therapeutically relevant 
concentration of antibody can be delivered across the BBB in an in vivo model (Yu et al., 2011). An 
important observation arose from this report in regards to antibody affinity toward the TfR.  It was 
discovered that the antibody required a lower binding affinity (~100 nanomolar), in order for it to be 
released from the TfR upon internalisation (Yu et al., 2011). Given the promise behind this delivery 
technique, this observation will be of great importance for future research and development.   
While this method has shown promising results, which suggest it may be a suitable method for treating 
TNBC brain metastases, there are still some limitations which need to be addressed. For instance, if this 
method to overcome the BBB was employed to increase chemotherapeutic accumulation in the brain, 
then the issue of neurotoxicity remains in play as the indiscriminate nature of the chemotherapeutics 
has not been addressed. This could be overcome by the development of a bifunctional modality in which 
the TfR is used to get the drugs into the brain and a marker on the TNBC cells is targeted to deliver the 
therapeutics specifically to the cancerous population. Given the lack of hormone receptors on TNBC in 
combination with the lack of targeted therapies currently available, such treatment options are limited. 
However, through targeting a CSC marker overexpressed on the TNBC this limitation could be 
overcome.  
Aptamers as a targeted novel treatment and diagnostic method for TNBC brain 
metastases 
Nucleic acid based aptamers are an emerging field of novel therapeutics, which in some aspects can be 
considered superior to conventional therapeutics used in cancer treatment and diagnosis. Development 
of aptamers began in 1990, following the ground breaking development of the polymerase chain 
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reaction (PCR), which had a key influence on molecular biology (Mayer, 2009).  The development of 
aptamers involved the influence of three independent research groups, with each group contributing 
independently by documenting the isolation of a single stranded nucleic acid with pre-defined functions 
(Ellington and Szostak, 1990b, Tuerk and Gold, 1990, Robertson and Joyce, 1990). Following their 
discovery of RNA molecules that bound to an organic dye, Ellington and Szostak defined the molecules 
as aptamers, a word chimera built from the Latin ‘aptus’ (to fit) and the Greek ‘meros’ (part) (Mayer, 
2009, Ellington and Szostak, 1990a). Chemically synthesised, aptamers bind to their target molecules 
with high affinity and specificity through shape recognition, similar to that of antibodies. Upon 
recognition and association with their target, aptamers form molecular architectures in which their 
target becomes an intrinsic part of the biomolecular structure (Hermann and Patel, 2000). 
Systematic Evolution of Ligands by Exponential Enrichment 
The chemical generation of aptamers, a process known as the systematic evolution of ligands by 
exponential enrichment (SELEX), is a well-established technology, which generates oligonucleotides 
with high target affinity (Figure 1.7). Characterised by a number of iterative rounds of selection, SELEX 
consists of five main steps: binding, partition, elution, amplification, and conditioning (Stoltenburg et al., 
2007). Firstly, the target ligand is incubated with a large random library of oligonucleotides, followed by 
the removal of non-binding and low-binding sequences, and then the bound sequences are eluted and 
amplified using PCR to be used in subsequent rounds of selection (Stoltenburg et al., 2007). After the 
final round of selection, the generated aptamers can be sequenced and characterised. Based on this 
technology, aptamers can be developed to bind to a number of different classes of targets, from single 
molecules to complex targets such as whole cells or organisms (Stoltenburg et al., 2007). While the 
selection process is characterised by repetition of the aforementioned steps, there is no standardised 
SELEX protocol, the overall design of the selection conditions depends on a number of factors, mainly 
the library, the target, desired features, and aptamer application (Stoltenburg et al., 2007).  
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Figure 1.7: The Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Initially a 
desired target ligand is exposed to a random pool of chemically synthesised oligonucleotides. Low and 
non-binding species are removed while the binding species are eluted and amplified subsequent to use 
in the next selection round. Following the completion of the final round of SELEX aptamers can then be 
sequenced and characterised. Figure adapted from (Shigdar et al., 2011c).  
 
Advantages and limitations of aptamers 
Aptamers, which function by molecular recognition, can be developed for therapeutic applications with 
the same intended function as antibodies, such as drug delivery vehicles. Though analogous to their 
protein counterpart in regards to target recognition and application, aptamers posess numerous key 
advantages, the main being their size, production process and nucleic acid structure. The significantly 
smaller size of aptamers (6-10 kDa vs. 150 kDa) allows for greater tissue penetration and permits their 
access to biological compartments inaccessible to antibodies (Zhou et al., 2012). The chemical 
generation of aptamers guarantees consistent production and is relatively inexpensive in comparison to 
the laborious and inconsistent in vitro or in vivo production of antibodies (Council, 1999). Finally, the 
nucleic acid composition of the aptamers offers significant advantage over the protein nature of 
antibodies in regards to structural stability. While antibodies are irreversibly denatured when exposed 
to varying physical conditions such as temperature and pH, aptamers are insensitive to these changes, 
retaining the ability to return to their original confirmations following exposure (Adler et al., 2008). Of 
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most importance is the ease in which aptamers can be chemically modified to address concerns 
regarding their applicability within a physiological environment.   
The in vivo half-life of an aptamer plays an integral role in its development toward therapeutic 
application. Both RNA and DNA are naturally susceptible to nuclease degradation, with unmodified DNA 
reported to have the longest half-life of approximately 60 minutes compared to a mere few seconds for 
RNA (White et al., 2000). Therefore, it is important to ensure they remain within systemic circulation for 
a required minimum period of time and are not degraded by serum nucleases (Keefe et al., 2010). 
Numerous modifications can be introduced to address these concerns but problems arise as to when to 
incorporate them, Pre- or Post-SELEX. Modifications made following the selection process have the 
potential to influence the aptamers’ binding affinity and selectivity. Fortunately, polymerases have been 
discovered that enable some of these modifications to be incorporated during the RNA transcription 
reaction, such as T7 RNA polymerase and AMV reverse transcriptase (Padilla and Sousa, 1999, 
Burmeister et al., 2005, Sawai et al., 2001). DNA polymerase chemistry has significantly lagged behind 
the ability to use RNA polymerases. Until recently there were no DNA polymerases commercially 
available that are capable of inserting modified nucleotides during the PCR reaction. In 2010, Kuwahara 
et al. demonstrated that KOD Dash DNA polymerase, derived from Thermococcus kodakaraensis, is very 
suitable for amplifying modified DNA by PCR using the C5-substituted thymidine analogue (Sawai et al., 
2001). Various DNA polymerases, including KOD Dash, Phusion High Fidelity, Superscript III and the T7 
polymerase are capable of incorporating modified nucleotides into RNA and DNA strands. Following 
evaluation, it was established that the KOD Dash DNA polymerase is the most efficient for incorporation 
of modified DNA as it is more tolerant towards base and sugar modifications than the aforementioned 
polymerases (Kuwahara and Sugimoto, 2010, Kuwahara et al., 2010). 
The majority of structural modifications employed to address the inadequate serum stability concern 
the sugar component of the nucleic acid. In particular the most prominent modifications are engineered 
at the 2’-position of the sugar, the natural site of nucleophilic attack (Adler et al., 2008, Mayer, 2009).  
Removal of the 2’-hydroxyl group normally occupying this position has been shown to aid in stronger-
base pairing with the target, ultimately leading to increased specificity in addition to increased nuclease 
resistance (Mayer, 2009). These modifications include the incorporation of fluoro (F), amino (NH2), alkyl 
and thio groups (Figure 1.8). The inclusion of these modifications greatly increases the half-lives of 
aptamers, with the inclusion of 2’-F and 2’-NH2 modifications in the unmodified RNA trypanosome 
aptamer reported to increase its half-life from less than one second up to thirty-six hours (Adler et al., 
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2008). In addition to these structural modifications, a key factor in the development of oligonucleotides 
for therapeutic application has been the inclusion of locked (LNA) and unlocked nucleic acids (UNA).  
 
 
Figure 1.8: Structures of the modified nucleotide bases. The ribose sugar of the RNA base can be 
modified at the 2′-OH (R) group by substitution with fluoro, methoxy, thio or amino groups; The 
structure of LNA is locked in place by the presence of a methylene bridge; The flexible structure of UNA 
results from the loss of C2’-C3’ bond.  Figure adapted from (Campbell and Wengel, 2011). 
 
Developed almost two decades ago, LNA and UNA are both RNA analogues that can be incorporated 
into oligonucleotide structures (Figure 1.8). Characterised by their structurally rigid conformation and 
generated by the presence of a methylene linkage present between the 2’-oxygen of the ribose sugar 
and the 4’-carbon, LNAs were developed in 1998 by the laboratories of Jesper Wengel and Takeshi 
Imanishi (Obika et al., 1998, Koshkin et al., 1998). In contrast to this, UNAs are highly flexible as a result 
of their acyclic structure formed by the missing bonds between the 2’-carbon and 3’-carbon of the ribose 
sugar. While both are nuclease resistant, in comparison to UNAs, there has been a lot more interest in 
the inclusion of LNAs into aptamer structures to improve therapeutic applicability. The inclusion of LNAs, 
into an aptamer targeting tenascin-C, a protein expressed abundantly and continuously in 
neovasculature and tumour stroma, not only increased the aptamer half-life (42 hours to 52 hours) and 
also increased aptamer binding affinity (Hicke et al., 2006, Schmidt et al., 2004).  
Applications of aptamers in cancer therapy  
Aptamers have the ability to be employed in a range of pharmacological areas, including applications 
such as drug discovery, diagnostics, molecular imaging, drug delivery vehicles and as protein inhibitors 
or modulators. At present, only one aptamer, Macugen, has been approved by the US Food and Drug 
Administration (FDA) while several aptamers are currently in clinical trials (Table 1.6).  Approved by the 
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FDA in 2004 Macugen is used for the treatment of macular degeneration. This aptamer functions 
through the inhibition of an isoform of VEGF, thus ultimately inhibiting angiogenesis (Ni et al., 2011).  
Table 1.6: A selection of current therapeutic aptamers undergoing clinical trials. Adapted 
from (Sundaram et al., 2013),(Yu et al., 2016b)  and 
http://clinicaltrials.gov/ct2/results?term=aptamer&pg=1. 
Therapeutic purpose Name Status 
Cancer 
AS1411 Phase II ongoing 
NOX-A12 Phase II ongoing 
Coagulation 
ARC1779 Phase II ongoing 
BAX499 Phase I ongoing 
NOX-H94 Phase II ongoing 
Inflammation NOX-E36 Phase II ongoing 
Macular degeneration 
ARC1905 Phase I completed 
E10030 Phase II await 
Pegaptanib FDA approved 
 
Aptamers in cancer imaging  
Given their ability to be generated against a wide variety of targets in combination with their sensitivity, 
aptamers are highly attractive tools for cancer imaging and diagnosis. Molecular imaging depends on 
the use of specific probes to visualise a specific target or biological processes. While the development of 
these ligands has focused on utilising peptides and antibodies, the use of aptamers as alternative 
molecular probes is being explored given their advantages over the protein counterparts, such as 
superior tissue penetration and signal-to-noise ratio (Wang and Farokhzad, 2014, Yin et al., 2012, Shi et 
al., 2010). Through the introduction of chemical modifications required for specific imaging techniques, 
aptamers can easily replace the currently employed probes. As aptamers are chemically synthesised, 
modifications can be easily introduced at the 5’ end or 3’ end, or in the middle of their structure through 
phosphoramidite chemistry, including the attachment of fluorophores, magnetic resonance imaging 
(MRI) contrast agents and radioisotopes (Wu et al., 2015). However, as these modifications are 
introduced post-SELEX, it is imperative to assess their influence on aptamer affinity and specificity. 
Aptamers conjugated with these imaging agents have been used in the detection of primary tumours 
and metastases in in vivo models (Wang and Farokhzad, 2014).  
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Positron electron tomography (PET) is a commonly used diagnostic imaging tools in the cancer field. This 
imaging method involves the injection of a small amount of a radioactive compound into the patient’s 
body, which then accumulates in the body where it has an affinity and gives off energy in the form of 
gamma rays. As this technique relies upon the accumulation of the probe along with its detection, it is 
difficult to find a suitable probe with good target-to-background signals, low toxicity and suitable stability 
(Dougherty et al., 2015). The affinity and specificity of aptamers make them highly attractive for 
development as molecular imaging probes for PET imaging. For an aptamer to become an imaging 
probe it first has to be modified to include a chelating moiety, such as DOTA or NOTA. Following this 
conjugation, the aptamer is then radiolabelled through the attachment of the radio nucleotide to the 
chelator.  Because of their chemical synthesis, the modification of aptamers with chelators i is a simple 
process. In 2006, researchers radiolabelled the TTA1  RNA aptamer for tenascin-C using 99mTc and tested 
its ability to bind to and enter cells (Hicke et al., 2006). Following intravenous injection, the radiolabelled 
aptamer was taken up rapidly by the tumour cells, with a maximal tumour dose observed within 10 
minutes of injection, 6% ID/g (Hicke et al., 2006). In addition to this, rapid blood clearance and deep 
tumour penetration were observed (Hicke et al., 2006). More recently, Peive et al. conducted an in vivo 
study investigating the imaging ability of aptamers against MUC1 labelled with 99mTc (Pieve et al., 2009). 
Similar to the TTA1 aptamer, the two aptamer probes cleared rapidly from the bloodstream and 
targeted the MUC1-expressing cells (Pieve et al., 2009). However, aptamer uptake was considerably 
reduced compared to the TTA1 aptamer, with the highest percentage of injected dose, 0.14% ID/g, at 5 
hours post injection (Pieve et al., 2009). Despite the results surrounding the clinical application of 
aptamers as imaging probes for PET imaging, due to limited studies, their safety remains inconclusive 
and therefore they have not yet progressed to the clinical setting.  
Fluorescence imaging is becoming a major tool for cancer diagnosis and imaging. An essential technique 
in understanding disease pathology and progression, this imaging technique allows visualisation of 
molecular processes at both the cellular and organism level (Wang and Farokhzad, 2014).  As this 
procedure relies upon fluorescently-labelled target specific probes with high sensitivity and specificity, 
aptamers are highly suitable imaging probes. While aptamers themselves are not fluorescent, 
fluorophores can be modified at the 5’ or 3’ end of their sequence, turning them into suitable fluorescent 
imaging probes.  The use of aptamers as fluorescent imaging probes has been extensively explored in 
the in vitro and in vivo setting. In 2011, Kunii and colleagues reported a FITC-labelled DNA aptamer for 
the detection of a specific type of small cell lung cancer cells (SCLC), SBC3 (Kunii et al., 2011).  Using 
confocal microscopy, a strong fluorescent signal was detected on the targeted SCLC cells, SBC3, and not 
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on other types of SCLC cells, RERF-LC-MA and DMS53, demonstrating the highly selective nature of the 
aptamer (Kunii et al., 2011). To be viable imaging probes for diagnostic and intraoperative detection of 
cancer cells, penetration into the tumour core is an essential pre-requisite. While antibodies have been 
considered the most specific imaging probes for a number of years, their ability to penetrate into the 
tumour core has been questioned (Thurber et al., 2008, Adams et al., 2001). Given their significantly 
smaller size, superior tissue penetration is one of the major advantages aptamers hold over their protein 
counterparts. To evaluate this, Martinez and colleagues compared the use of a fluorescently labelled 
anti-MUC1 aptamer and antibody as imaging agents using spheroid assemblies as solid tumour models 
(Martinez et al., 2014). Using confocal microscopy to detect the image probes inside the spheroid, on 
the central z-plane image it was evident that the anti-MUC1 antibody was only present on the peripheral 
cells of the spheroid (Martinez et al., 2014). In contrast to this, the MUC1 aptamer was present on 
majority of the surface of the central z-plane image, demonstrating superior tumour sphere penetration 
over the anti-MUC1 antibody (Martinez et al., 2014). While this study highlighted the superiority of 
aptamers over antibodies as imaging probes in vitro, it is important to test that these functions are 
retained in an in vivo environment.   
Aptamer mediated drug delivery  
The specific targeting ability of aptamers, combined with their quick uptake and tumour penetration 
abilities make them an excellent platform for the delivery of cytotoxic agents. Currently, cytotoxic agents 
employed to treat malignancies are indiscriminate and non-specific, meaning they not only kill the 
cancerous cells but also healthy cells, leading to severe and dose-limiting side effects (Wang et al., 2012). 
In addition to this, the therapeutic efficiencies of these agents decreases throughout the treatment 
course as a result of acquired resistance (Porciani et al., 2015). DOX is one of the most widely used 
chemotherapeutic agents employed for the treatment of a number of cancers. The anticancer effect of 
DOX is the result of its ability to intercalate into DNA, disrupting replication and transcription. Given this, 
the nucleic acid nature of aptamers can be exploited to intercalate DOX into the double stranded non-
binding region of the structure, resulting in the development of a specific drug delivery vehicle. 
Development of aptamer DOX conjugates has been extensively reported in the literature (Huang et al., 
2009, Subramanian et al., 2012, Xu et al., 2013b, Yu et al., 2016a, Porciani et al., 2015, Bagalkot et al., 
2006). In 2006, Bagalkot et al. reported the specific delivery of DOX into prostate cancer cells utilising an 
aptamer which targets prostate specific membrane antigen (PMSA) expressed on prostate cancer cells 
(Bagalkot et al., 2006). While in this study the cytotoxic effect of the aptamer DOX conjugate was 
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comparable to that of DOX, the cytotoxic effect of the conjugate on the negative cell line was significantly 
reduced, whereas a similar cytotoxic effect by DOX was observed on both cell lines (Bagalkot et al., 
2006). Results similar to this were observed in 2016 when Yu and colleagues intercalated DOX into an 
aptamer targeting HepG2, a line of human liver carcinoma cells (Yu et al., 2016a). Through this 
intercalation Yu and colleagues demonstrated that the cytotoxic effect of DOX on the control cells was 
significantly reduced compared to free DOX (Yu et al., 2016a). However, only a slight cytotoxic difference 
was observed between the two treatments, with the aptamer-DOX conjugate having a slightly higher 
cytotoxic effect. As DOX is noncovalently intercalated into the aptamer structure, this delivery method 
is only effective for chemotherapeutics with the option for intercalation.  
Given their high loading drug capacity, over the past decade nanoparticles have been developed as anti-
cancer drug delivery vehicles (Orilall and Wiesner, 2011). A wide variety of nanomaterials have been 
explored for the targeted delivery of chemotherapeutics, including liposomes, polymers, gold, and 
poly(lactic-co-glycolic-acid) nanoparticles (PLGA) (Dhar et al., 2008, Dhar et al., 2011, Farokhzad et al., 
2006, Zhu et al., 2015). While alone these vehicles lack specific targeting, once combined with an active 
targeting mechanism, such as aptamers, highly specific drug delivery vehicles are developed. Through 
functionalising PLGA-PEG nanoparticles encapsulating Paclitaxel with the AS1411 aptamer which targets 
nucleolin, Guo et al. were able to demonstrate superior in vivo results compared to the non-targeted 
nanoparticles (Guo et al., 2011). Following intravenous administration of each treatment over a 20 day 
period, the aptamer guided nanoparticles significantly prolonged survival comparted to the animals 
treated with the unguided nanoparticles and Paclitaxel (Guo et al., 2011). While improving the specificity 
of chemotherapeutics is a great step towards the specific treatment of cancer cells, aptamers have the 
potential to further enhance therapeutic efficacy through targeting proteins associated with therapeutic 
resistance. 
Therapeutic resistance is a major cause of treatment failure in a number of a solid tumours. The high 
specificity of aptamers makes them suitable for development as delivery vehicles to tackle the issue of 
chemo-resistance. This can be achieved through the delivery of siRNA to knock down proteins or 
through the use of decoy molecules.  Wang and colleagues generated an aptamer chimera to specifically 
deliver siRNA to EpCAM positive tumour cells to silence survivin, a protein involved in the inhibition of 
apoptosis, promotion of angiogenesis, and chemo resistance (Wang et al., 2015). Using the EpCAM 
aptamer-siRNA chimera, Wang et al. were able to sufficiently silence survivin to reverse chemo 
resistance in a DOX resistance breast cancer cell line. The reversal of chemo resistance was validated 
through the combined treatment of the chimera with low doses of DOX in mice bearing chemo resistant 
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tumours (Wang et al., 2015). Through this treatment, tumour growth was substantially supressed and 
the mice receiving the combined treatment had significantly longer survival times compared to those 
receiving DOX alone (Wang et al., 2015). Although these results are very promising, given that the DOX 
was administered as an unconjugated drug, the issue of the indiscriminate targeting by cytotoxic agents 
remains. To resolve this issue, DOX could be conjugated into the EpCAM aptamer alone and 
administered in the same combined treatment plan.  Porciani et al. used this approach to enhance the 
chemo sensitivity of pancreatic cancer cells through conjugating a TfR aptamer with a decoy 
oligonucleotide which supresses DOX-induced apoptosis, and administering it in combination with DOX 
loaded TfR aptamer (Porciani et al., 2015). Through utilising the TfR aptamer to both target the cause of 
DOX resistance and to specifically deliver DOX in a combined treatment, Porciani et al. were able to 
significantly enhance the cytotoxic effect of DOX in vitro compared to aptamer DOX treatment alone 
(Porciani et al., 2015). While these results are yet to be confirmed in an in vivo model, they show great 
promise for the specific treatment of chemo resistant tumours. Furthermore, they highlight the great 
potential of aptamers to be developed to play multiple roles in the treatment of a single disease.  
TfR aptamers with the potential of crossing the BBB 
Ubiquitously expressed in normal cells at low levels and more highly expressed (approximately 100-fold 
up regulation) in cells with a high proliferation rate and on the endothelium of the BBB, the TfR has 
become an ideal target for cancer diagnosis and treatment (Daniels et al., 2012). Two methods exist in 
which this receptor can be targeted and have an effect on cancer cell progression. The first involves 
blocking the natural function of the receptor, iron homeostasis, which consequently leads to cancer cell 
death (Daniels et al., 2012). The second is the use of the receptor as a ferrying system to deliver 
therapeutic molecules into cancerous cells (Wilner et al., 2012). Tf, the natural ligand of this receptor has 
been widely employed as a transport vector for this method (Singh et al., 1998, Kratz et al., 1998, Elliott 
et al., 1988). The near saturation of the TfR from endogenous Tf in physiological conditions limits the 
applicability of Tf as a transport vehicle, as in order to ensure adequate delivery of the therapeutic 
payloads exceedingly high levels would be required (Porciani et al., 2014). Aptamers are a promising 
alternative to overcome this limitation given their ability to target different sites on the TfR and the 
possibility of generating them with higher affinities towards TfR than natural Tf (Porciani et al., 2014).  
Recently, Chen et al. reported the development of DNA and RNA aptamers that selectively recognise 
the extracellular domain of the mouse TfR (Chen et al., 2008). Originally 64 nucleotides long, Chen and 
colleagues truncated the selected DNA aptamer, GS24, to 50 nucleotides while still maintaining 
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sensitivity and selectivity (Chen et al., 2008). While demonstrating attractive binding properties for 
therapeutic application, the large size of this aptamer limits its therapeutic capabilities. Therefore,  this 
aptamer was further truncated to 35 nucleotides by Porciani et al. (Porciani et al., 2014). Unfortunately, 
this truncation lead to a significant loss of binding affinity, with a 5-fold higher dissociation constant 
toward the mouse TfR determined for the newly truncated aptamer (Porciani et al., 2014). This issue 
was resolved through the introduction of mutations into the stem region of the aptamer, resulting in an 
aptamer with superior properties to the original GS24 aptamer (Porciani et al., 2014). Of most 
importance from this study the establishment that the truncated aptamer was cross reactive between 
mouse and human species (Porciani et al., 2014). During the development of new medicinal therapies, 
a fundamental problem which arises and hinders progression from bench top to clinical trials is the 
efficacy of the therapy within in vivo animal models (White et al., 2001). Therefore, because the TfR 
aptamer generated by Porciani and colleagues cross react between mouse and human, it is highly 
attractive for further functionalisation and to be developed for therapeutic application.  
Developing a bifunctional aptamer to target TNBC brain metastases 
The therapeutic potential of mono-specific nucleic acid aptamers can be further enhanced through the 
production of bifunctional aptamers. Developed by fusing two aptamer binding sequences, these 
aptamers are designed by two different pathways. The first entails the fusion of two aptamers with 
independent binding activities. Generation in this manner broadens the limited recognition capability of 
mono-functional aptamers, a highly attractive property for cancer therapeutics (Zhu et al., 2012). In 
2011, Min et al. reported the development of a bifunctional aptamer based DOX delivery vehicle (Min 
et al., 2011).  Through the conjugation of an RNA aptamer targeting PMSA positive cells, with a peptide 
aptamer specific for PMSA negative cells, DOX was synchronously delivered to two types of prostate 
cancer cells and resultantly induced cell cytotoxicity, addressing the underlying problem of solid tumour 
heterogeneity (Min et al., 2011). Similarly, the following year a bifunctional aptamer targeting leukaemia 
subtypes, sgc8c-sgda5a aptamer, was developed which elicited bi-specific cytotoxicity (Zhu et al., 2012). 
The second method involves the joining of two aptamer binding sequences in which the binding of the 
first aptamer influences the binding of the second (Le et al., 2013). Synthesis in this manner opens up 
the possibility of delivering drug payloads to sites within the body which may not be accessible to drug 
alone due to restrictive transport mechanisms. To date there are no aptamers reported which exploit 
this highly attractive generation method to target tumours. Given the highly restrictive nature of the 
BBB, this method could be utilised to generate a bifunctional aptamer, which targets the TfR to transport 
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chemotherapeutic agents across the barrier and specifically delivers them to TNBC brain metastases by 
targeting CSC markers expressed on the tumour cell surface membrane. 
Project aims and hypothesis  
The overarching hypothesis of this study is that the generation of a bifunctional transferrin receptor 
EpCAM aptamer and its subsequent conjugation to chemotherapeutic agents will produce a specific 
delivery vehicle capable of crossing the BBB and delivering its payload to EpCAM positive TNBC brain 
metastases.  
To test this hypothesis, this study aims to: (I) truncate the GS24 transferrin receptor aptamer to its 
shortest functional length while maintaining specificity and selectivity, (II) develop a bifunctional 
aptamer targeting the mouse transferrin receptor and EpCAM through the fusion of the truncated GS24 
aptamer with the human EpCAM aptamer and (III) intercalate DOX into the stem region of the 
generated bifunctional aptamer to specifically deliver cytotoxic agents to EpCAM positive brain 
metastases.   
Conclusion 
Cancer is a major public health problem worldwide. While the landscape of cancer treatment has 
drastically changed over the last few decades, there still remains no known cure for most types of 
cancers. Currently, the most universally employed anti-cancer treatments are chemotherapeutics. 
These treatments are non-specific and indiscriminate, and result in severe dose-limiting side effects. 
Although these treatments increase TNBC patient survival time, they are believed to only targetthe bulk 
of tumour and not the CSCs. Thus, treatment with current therapeutics allows more time for metastasis 
to occur throughout the body, in particular to the brain.  Given the non-specific nature of these 
treatments and the rise in metastatic brain lesions, there is great need for the development of novel 
treatments with high tumour specificity and that are capable of entering the brain via systemic 
circulation. By completing the aims listed above, this project will result in the development of a next 
generation drug delivery system capable of specifically targeting brain metastases. This targeted delivery 
system will spare healthy brain tissue by specifically targeting the entire tumourigenic population and 
reducing the required concentration of drug to treat the malignancies, leading to reduced healthcare 
costs for the patient and the public healthcare system.   
 48 
 
Chapter 2: Truncation and mutation of a transferrin 
receptor aptamer enhances binding affinity 
 
This chapter has been published in the form it is presented here. 
 
Joanna Macdonald, Patrick Houghton, Dongxi Xiang, Wei Duan and Sarah Shigdar. Truncation and 
Mutation of a Transferrin Receptor Aptamer Enhances Binding Affinity. Published in Nucleic Acid 
Therapeutics. 2016;26(6):348-54.  
Preface  
Classified as the most frequent cancer in the central nervous system, brain metastases are ten times 
more common than primary brain tumours. Situated within the safe sanctuary of the brain, protected 
by the blood brain barrier (BBB), current management strategies are limited, thus the overall survival for 
diagnosed patients is very poor. An emerging strategy to overcome this barrier is to target active 
transport mechanisms present on the BBB. Given its high expression levels, the TfR has been studied 
extensively for this purpose. While promising results have been produced using monoclonal antibodies, 
nucleic acid based aptamers have emerged as a superior alternative due to their increased stability, 
safety profile and minimal batch-to-batch variation. An aptamer targeting the extracellular domain of 
the mouse transferrin receptor was reported in 2008. However, given the large size of this aptamer, 64-
nucleotides, and its complex structure, it is not suitable for therapeutic development. With this 
knowledge, we aimed to truncate the aptamer to its shortest functional length without disrupting 
sensitivity or specificity. In addition to increasing therapeutic potential, truncation decreases synthesis 
costs and can potentially improve binding affinity. Following structural analysis, a single stranded region 
within the complex aptamer structure was chosen as the site for truncation, generating an aptamer with 
a low affinity towards the mouse transferrin receptor. To further modulate this affinity random 
mutations were introduced into the single stranded binding region. From this, in this study we have 
engineered four DNA aptamers specific for the mouse transferrin receptor which can act as a transport 
system for the delivery of therapeutics across the BBB.   
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Preface 
Chapter 2 reports the rational truncation of the GS24 transferrin receptor to its smallest functional unit 
while still maintaining specificity and sensitivity. Through the introduction of mutations into the single 
stranded binding loop, substituting all four bases, the binding affinity of the aptamer was enhanced. 
Furthermore, it was confirmed that the aptamer is internalised via receptor mediated transcytosis, 
indicating that it could possess the ability to transcytose the BBB and enter the brain microenvironment.  
The small size of this aptamer is advantageous for future application as a drug delivery vehicle for the 
treatment of brain disorders, such as brain metastases. However once across the barrier, it would target 
the transferrin receptor leading to non-specific drug delivery. To resolve this issue, this study aimed to 
generate a bifunctional aptamer through the fusion of the TfRA4 generated in the previous chapter with 
an aptamer targeting a cell surface marker over expressed on metastatic brain cancer cells. Given its 
overexpression on a number of solid cancers with a high incidence of metastasising to the brain, EpCAM 
was chosen as the target.  Similar to the previous chapter, the selected EpCAM aptamer was large and 
possessed a complex structure and therefore needed to be truncated to a suitable length for fusion with 
the TfRA4 aptamer.  Following structural analysis, three potential single stranded binding regions were 
identified and the aptamer was truncated to generate three aptamers consisting of these regions. One 
of the EpCAM targeting aptamers, EpA, was identified as the most suitable candidate for the bifunctional 
aptamer, and was therefore fused with the TfRA4 aptamer to generate the bifunctional aptamer. To 
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further modulate this affinity random mutations were introduced into the single stranded binding 
region. From this, a bifunctional aptamer was generated which binds with moderate affinity to both the 
TfR and EpCAM and is capable of traversing the BBB both in vitro and in vivo. The results using this 
aptamer demonstrate its potential for further development as a drug delivery vehicle for the treatment 
of EpCAM positive metastatic brain tumours.  
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Chapter 4: Development of a bifunctional aptamer-
doxorubicin conjugate for the treatment of triple 
negative breast cancer brain metastases 
 
 
 
This chapter has been written in the style of a journal article but has not yet been 
published. 
 
 
Preface 
The results of Chapters 2 and 3 demonstrate the development of a bifunctional aptamer capable of 
transcytosing the BBB and targeting a specific cell population. While the results produced thus far 
illustrate the diagnostic potential of the aptamer, alone the aptamer lacks a therapeutic effect.  
Therefore, the following study investigated the development of the aptamer as a drug delivery vehicle 
and its ability to specifically target TNBC cells subsequent to transcytosing the BBB in vitro. This was 
achieved through the intercalation of DOX, a chemotherapeutic agent commonly employed in the 
treatment of TNBC, into the aptamers double stranded non-binding region. In this study following DOX 
intercalation it was established the bifunctional aptamer has the ability to traverse the BBB in vitro and 
deliver its cytotoxic payload specifically to EpCAM positive TNBC cells. These promising results serve as 
a platform for the further development of this aptamer for the treatment of TNBC brain metastases.  
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Australia 
 
Abstract 
The treatment of triple negative breast cancer brain metastases is greatly hindered by the presence of 
the blood brain barrier. Lining the blood vessels of the brain, this barrier restricts the overwhelming 
majority of small molecules and chemotherapeutics from entering the brain. A novel approach to 
surpass this barrier is the development of therapeutics which target receptor mediated transport 
mechanisms present on the endothelial cell membranes.  Therefore, we intercalated doxorubicin into a 
bifunctional aptamer which targets the transferrin receptor and epithelial cell adhesion molecule-
expressing cancer cells. This generated a therapeutic delivery vehicle potentially capable of 
transcytosing through the blood brain barrier and delivering the cytotoxic payload to the cancer cells. 
The ability of the aptamer to transcytose the blood brain barrier was assessed in vitro following 
incubation with aptamer drug conjugates at an equivalent doxorubicin concentration of 1 micro molar. 
This study has shown that through the intercalation of doxorubicin into the bifunctional aptamer, a 
therapeutic delivery vehicle can be developed for the effective treatment of epithelial cell adhesion 
molecule positive brain metastases. 
Introduction 
Classified as the most frequent cancer in the central nervous system, brain metastases are ten times 
more common than primary brain tumours (Walbert and Gilbert, 2009, Fortin, 2012). While treatment 
advances in conjunction with timely imaging and diagnostic applications have led to an increase in 
progression free survival of primary malignancies, the battle for many cancer patients is not over 
following the release of recent epidemiological data which highlighted an increase in the incidence and 
prevalence of brain metastasis (Singh et al., 2014, Langley and Fidler, 2013). After lung cancer, breast 
cancer is the  most frequent cancer to metastasise to the brain (Leone and Leone, 2015, Witzel et al., 
2016).   Prognosis for these patients is influenced by a number of factors, including time of diagnosis, the 
number of metastatic lesions and the tumour molecular subtype. Of the four molecular distinct 
 82 
 
subtypes, triple negative breast cancer (TNBC) has the highest frequency of metastasis to the brain. 
Accounting for 15-20% of breast cancers, TNBC is defined by a lack of hormone receptors and HER2 
expression. This is turn has negative implications for available targeted treatment options, such as 
endocrine therapy, which are ineffective for this cancer subtype.  Consequently, combined with the 
highly aggressive nature of this subtype, patients with TNBC have the worst prognosis of all the 
molecular subtypes.  
The main objective when treating TNBC brain metastases is to maximise patient survival and functional 
state, without compromising neurological status. Similar to primary tumours, patient prognosis is poor 
given the highly aggressive nature of the tumour, combined with the lack of targeted therapeutics. 
Taking these factors into account, treatment is often multi-modal, utilising a combination of treatment 
options, including surgical resection, whole brain radiation therapy (WBRT), stereotactic radiotherapy 
(SRS), and traditional chemotherapy. The efficacy of these treatments is influenced by the number of 
lesions, their location, age and health status (Hardesty and Nakaji, 2016). While these combinations have 
shown to improve survival length by a few months, each is associated with a number of side effects, 
including neurocognitive dysfunction, nausea, serous otitis media and hair loss (McTyre et al., 2013, 
Patchell  et al., 1990).  Although used in the treatment of TNBC, the efficacy of chemotherapeutic agents 
such as doxorubicin (DOX) in the treatment of brain metastases is poor.  This is the result of two major 
limitations, the first being the restrictive nature of the blood brain barrier (BBB) and the second, the 
inability of these treatments to eradicate the tumourigenic population.    
Present at all levels of the vascular tree within the brain, the BBB is a major obstacle for therapeutics to 
overcome for the treatment of brain metastases. Composed of endothelial cells joined by highly 
polarised tight junctions, the BBB segregates the brain from the peripheral circulation, impeding the 
influx of blood borne molecules which may disturb brain homeostasis (Abbott et al., 2010, Ballabh et al., 
2004). The highly restrictive nature of the barrier prevents access of 98% of small molecules to the brain 
microenvironment (Gabathuler, 2010). Surpassing this barrier is the first obstacle in the specific delivery 
of chemotherapeutic agents to metastatic brain lesions. A novel approach to achieve this is the 
development of therapeutic modalities that hijack transport mechanisms present on endothelial cell 
membranes. This allows them to firstly pass through the BBB without disrupting it and increases drug 
delivery by allowing them to circumvent the efflux capacity of the BBB (Deeken and Loscher, 2007). 
Given its ubiquitous expression on the BBB, the transferrin receptor (TfR) is one receptor which has been 
exploited for this purpose.  The development of therapeutics targeting this pathway have previously 
been explored using antibodies (Yu et al., 2011, Xu et al., 2011).  In 2011, Yu and colleagues reported the 
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development of a low affinity antibody capable of exploiting the TfR, crossing the BBB and achieving a 
therapeutically relevant concentration of antibody within the brain in an in vivo model. Given the 
immunological risk antibodies pose, a novel therapeutic strategy is required (Yu et al., 2011). 
Nucleic acid aptamers are an emerging field of therapeutics, which can be considered superior to 
antibodies. Often referred to as chemical antibodies, aptamers are single stranded oligonucleotides 
which bind to their targets through shape recognition, allowing them to be developed for therapeutic 
applications with the same intended functions as antibodies (Stoltenburg et al., 2007). However, 
aptamers can be considered superior given their lack of immunogenicity, production process and 
significantly smaller size (Zhou et al., 2012, Keefe et al., 2010).  Recently, the development of an aptamer 
targeting the TfR with the ability to traverse the BBB was reported (Macdonald et al., 2017). While this 
aptamer is capable of penetrating into the brain, alone this aptamer has no therapeutic effect. The 
nucleic acid composition of aptamers allows them to serve as drug delivery vehicles, in particular the 
delivery of anthracycline chemotherapeutics such as DOX, through intercalating into DNA. Intercalated 
in the aptamer’s structure, DOX is specifically internalised into the target cell via endocytosis, thus 
eliminating indiscriminate side effects and increasing the intracellular drug concentration as drug efflux 
pumps present on the cell membrane are bypassed. The development of aptamer-DOX conjugates has 
been extensively reported within the literature (Huang et al., 2009, Subramanian et al., 2012, Xu et al., 
2013a). With DOX intercalated in the TfR aptamer, the first limitation of chemotherapeutics (being 
incapable of traversing the BBB) could be resolved. While this resolves the first limitation, it then leads 
into the second limitation of specifically targeting the tumourigenic population and mitigating the 
neurotoxic side effects. 
Specific targeting can be achieved with therapeutics that target specific markers overexpressed on the 
tumourigenic population. First described 30 years ago, epithelial cell adhesion molecule (EpCAM) is a 
transmembrane glycoprotein overexpressed in the majority of solid cancers, including TNBC) (Soysal et 
al., 2013). Given its overexpression, EpCAM is therefore a promising target for directed therapies. This 
potential has been explored through the clinical investigation of a number of EpCAM antibodies (Münz 
et al., 2010).  While demonstrating some clinical benefit, it was found that some of the antibodies were 
poorly tolerated and resulted in pancreatitis (Münz et al., 2010, Schmidt et al., 2010). Following the 
discovery that these issues were the result of the high binding affinity of the antibody, they were 
resolved through the generation of an antibody with a moderate affinity (Schmidt et al., 2010).  
However, following patient stratification based on EpCAM expression, it was found that patients with 
high EpCAM expression levels responded more favourably to the antibody than those with low 
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expression (Schmidt et al., 2010). These results confirm that EpCAM is a good therapeutic target, 
however better modalities are required for efficacy to be demonstrated in patients with a 
heterogeneous expression of EpCAM. These limitations could be addressed through the use of 
aptamers. This has been explored through the generation of a RNA aptamer by Shigdar et al. which 
specifically binds with EpCAM followed by cellular internalisation (Shigdar et al., 2011b). This aptamer 
has the ability to specifically interact with a number of EpCAM expressing cancers, especially in the TNBC 
cell line MDA-MB-231, which has low level of EpCAM expression, but not with those with no expression 
(Shigdar et al., 2011b). The potential of this aptamer has also been explored as a drug delivery vehicle. 
In 2013, Subramanian et al. reported that through the conjugation of the aptamer with DOX, they were 
able to specifically deliver the drug to retinoblastoma cells in vitro, resulting in the inhibition of cellular 
proliferation (Subramanian et al., 2012). As the aptamer is internalised via receptor-mediated 
endocytosis, the drug bypasses the drug efflux pumps present on the cell membrane and targets drug 
resistant population.  
Given the potential of EpCAM as a therapeutic target, the generation of a bifunctional aptamer targeting 
the TfR and EpCAM has recently been reported for the treatment of brain metastases (Macdonald et al., 
2017). The ability of this aptamer to traverse the BBB in vitro and target EpCAM positive cancer cells has 
been confirmed, however alone this aptamer has no therapeutic effect. Therefore, here we describe 
the intercalation of DOX into the aptamer to develop a therapeutic delivery vehicle capable of crossing 
an in vitro BBB model via transcytosis, and specifically targeting brain metastases derived from EpCAM 
positive TNBC cells.  
Materials and methods  
Cell lines and Cell Culture 
The cell lines of mouse and human origin used in this study were purchased from the American Type 
Culture Collection. They are mouse brain endothelial cells (bEnd.3), human embryonic kidney cells 
(HEK293T) and human breast adenocarcinoma cells (MDA-MB-231). Cells were grown and maintained 
in culture with Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, Victoria, Australia) 
supplemented with 10% fetal calf serum (FCS). Cells were maintained at 37°C in a 5% CO2 atmosphere.  
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Aptamers 
The bifunctional aptamers were purchased from Integrated DNA Technologies (IDT, Coralville, IA) and 
HPLC purified. All oligonucleotide sequences were labelled with a TYE665 fluorophore on the 3’ end. The 
sequences were as follows: 
TEPP (TfR+ EpCAM+): 5’- GC GCG GTAC CGC GC TA ACG GA GGTTGCG TCC GT- 3’ 
TENP (TfR- EpCAM+): 5’- GC GCG TGCA CGC GC TA ACG GA GGTTGCG TCC GT-3’ 
TEPN (TfR+ EpCAM-): 5’- GC GCG GTAC CGC GC TA ACG GA TTCCTTT TCC GT-3’ 
TENN (TfR- EpCAM-): 5’- GC GCG TGCA CGC GC TA ACG GA TTCCTTT TCC GT- 3’ 
For experimental procedures aptamers were prepared at the desired concentration in 5 mM 
magnesium chloride (MgCl2) phosphate buffered saline (PBS) and folded into their three-dimensional 
structure using a thermocycler (PerkinElmer) (85°C for 5 min, slow cooling to 22°C over 10 min, and 37°C 
for 15 min). 
Development of aptamer-doxorubicin conjugate 
To develop the aptamer-DOX conjugates, DOX (44583; Sigma) was conjugated with the folded aptamers 
in conjugation buffer (0.1 M sodium acetate (CH3COONa), 0.05 M sodium chloride (NaCl), and 5 mM 
MgCl2 for 60 min at 75 RPM. The natural fluorescent property of DOX and its subsequent quenching 
following intercalation allowed efficient quantification of the conjugate molar ratio and loading 
efficiency. The conjugation molar ratio was determined through the incubation of varying aptamer 
concentrations with a fixed concentration of DOX. The fluorescent signal of varying ratios of the aptamer 
to DOX (0, 0.01, 0.04, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1) was measured in parallel with a 
standard curve of DOX using the VICTOR TM X5 Plate Reader (PerkinElmer Life).  
To separate the aptamer-DOX conjugates from the unconjugated DOX, the conjugation mixture was 
passed through Sephadex®G-10 medium column (1181442700; Sigma). To evaluate the concentration 
of doxorubicin intercalated into the aptamer, 30 µL of the conjugate mixture was added to 90 µL of 
acetonitrile. This solution was vortexed for 1 min followed by centrifugation for 5 min at 21,000 g.  Fifty 
microliters of the supernatant were analysed in parallel to a standard curve of free DOX using the 
VICTOR TM X5 Plate Reader (PerkinElmer Life) to establish the intercalated concentration. 
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Determination of aptamer affinity following DOX intercalation  
The dissociation constant (Kd) of the aptamer-DOX conjugates was determined by measuring aptamer 
binding to native protein targets using flow cytometric analysis. The cells of interest (5 x 105) were first 
incubated with binding buffer for 30 min (PBS containing 10% FCS, 0.1 mg/mL transfer ribonucleic acid 
(tRNA), 0.1 mg/mL bovine serum albumin (BSA)) followed by two washes with binding buffer prior to 
incubation with serial concentrations of TYE665-labelled aptamer-DOX conjugates prepared as 
described in the previous section (0 nM to 400 nM)  at the maximal calculated aptamer to DOX molar 
ratio in a 100 μL volume of binding buffer (PBS containing 10% FCS, 0.1 mg/mL tRNA, 0.1 mg/mL BSA) 
for 60 min at 37 °C. The cells were washed three times with PBS, resuspended in 100 μL PBS and 
subjected to flow cytometric analyses (FACS Canto II flow cytometer, Becton Dickinson). Unless 
otherwise specified, aptamer Kd was calculated from the normalized mean values for fluorescent 
intensity, from biological triplicates. 
Cellular uptake and retention of aptamer-doxorubicin conjugates  
Twenty-four hours before labelling, MDA-MB-231 and HEK293T cells were seeded at a density of 7.5 x 
104 cells/cm2 in an eight-chamber slide (LabTekII; Nunc). Following removal of media, cells were 
incubated in binding buffer (PBS containing 10% FCS, 0.1 mg/mL tRNA, 0.1 mg/mL BSA) at 37° C for 30 
min. Cells were then incubated with 1 µM DOX and aptamer-DOX conjugates at an equivalent DOX 
concentration of 1 µM for 60 min and 120 min at 37° C. Bisbenzimide Hoechst 33342 (3 μg/mL; Sigma) 
was added to the cells during the ﬁnal 10 min of incubation. Following each time point, the aptamer-
DOX and DOX solutions were removed and cells were washed 3 times for 5 min each in binding buffer 
prior to visualisation using a FluoView FV10i laser scanning confocal microscope (Olympus). To establish 
aptamer-DOX retention, following 120 min incubation cells were incubated for a further 24 h in DMEM 
before re-imaging. The captured images were then analysed using ImageJ to quantify DOX fluorescence, 
with 15 cells analysed in total.  
Mouse in vitro blood brain barrier transcytosis of aptamer-doxorubicin conjugates  
Transwell inserts (polyethylene terephthalate (PET) with 0.4 μm diameter pores) within a 24-well plate 
(COR3379; Corning) were incubated with 100 μL of 50% Collagen IV for 240 min at 37°C. Wells were 
filled with 500 μL of DMEM media, supplemented with 10% FCS, and transwell inserts were placed on 
top. BEnd.3 cells were then seeded onto the luminal side of the filter at a density of 1.34 x 105 cells per 
filter and were allowed to grow for 6 days. Media in the luminal and abluminal compartments was 
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replaced on day 2 and day 4 in order to supplement the growth of the monolayer. On day 5, media in 
both compartments were replaced with enhanced media (DMEM: Ham’s F12 (1:1), 550 nM 
hydrocortisone, 32 μM cAMP, 17.5 μM aminophylline, 1 μM retinoic acid, 5 μg/mL insulin, 2.75 μg/mL 
transferrin and 2.5 ng/mL sodium selenite). On day 6, MDA-MB-231 and HEK293T cells were seeded 
into the lower compartment at a density of 1 x 105 cells per well, and allowed to settle for 180 min. 
Media was then removed from the upper compartments, and 100 μL of aptamer-DOX conjugates at an 
equivalent DOX concentration of 1 µM was pipetted on top of the transwell membrane. In order to 
differentiate the cell lines, an anti-EpCAM antibody (347197; BD Biosciences) was added to the lower 
compartment in the last hour of aptamer incubation at a concentration of 10 μg/ml. Following a 180 
min incubation at 37° C, media in both compartments were removed. Cells were then resuspended in 
100 μL of PBS and 2 μL of Hoechst nuclear stain (10 mg/mL) was added and allowed to incubate for 10 
min. Cells were then trypsinized, and washed three times in 100 μL of PBS before viewing under a 
FluoView FV10i laser scanning confocal microscope (Olympus). 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 6.0 (San Diego, CA). An unpaired t test was 
used for comparisons between two experimental groups. Unless otherwise indicated, all results were 
averaged from biological triplicates and values are reported as means ± SEM. P < 0.05 was considered 
statistically significant. 
Results and discussion 
Development of aptamer-doxorubicin conjugate 
To generate a targeted drug carrier capable of transcytosing the BBB and delivering its cytotoxic payload 
to EpCAM positive TNBC brain metastases, doxorubicin was conjugated with the bifunctional aptamer. 
The potential sites of DOX intercalation in the bifunctional aptamer were analysed using the structure 
prediction software, Mfold (Zuker, 2003). The predicted bifunctional secondary structure consists of two 
hairpin structures connected by double stranded regions. The site of DOX intercalation is between the 
GC and CG sequences in the double stranded region of the aptamer, giving the aptamer six sites for 
intercalation (Figure 4.1).  
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Figure 4.1: Schematic diagram of the predicted intercalation of DOX in the bifunctional 
aptamer. Predicted sites for DOX intercalation represented by red rectangles.  
 
To determine the optimal molar ratio for loading DOX into the bifunctional aptamer, a conjugation assay 
was performed with sequential increases of aptamer to DOX. For this, a quantitative assessment was 
employed which utilised the fluorescent quenching of DOX subsequent to its intercalation into double 
stranded DNA. Shown in Figure 4.2, the natural fluorescent signal of DOX was gradually quenched upon 
intercalation with increasing concentrations of each bifunctional aptamer demonstrated by the 
quenching of DOX fluorescence. For all four bifunctional aptamers, the quenching of DOX fluorescence 
reached a plateau at the molar ratio of 0.4 aptamer to DOX after 60 min incubation, suggesting that 
approximately 2.5 molecules of DOX were intercalated per aptamer.  
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Figure 4.2. Determination of aptamer to DOX molar ratio. The fluorescent quenching of DOX at 
a fixed concentration with an increasing aptamer to DOX molar ratio (0.01, 0.04, 0.08, 0.1, 0.2, 0.3, 0.4, 
0.5, 0.6, 0.7, 0.8, 0.9 and 1) was measured after 60 min incubation at 37°C 75 RPM. (A) TEPP-DOX; (B) 
TEPN-DOX; (C) TENP-DOX; and (D) TENN-DOX. Data shown are mean ± SEM. (n=3). 
 
Preservation of aptamer specificity and selectivity following DOX conjugation 
Introducing modifications or intercalating agents into the stem regions of aptamers can lead to a loss of 
selectivity and/or sensitivity (Schmidt et al., 2004). Therefore, following intercalation a biological assay 
utilising human and mouse cell lines was employed to ensure the aptamer-DOX conjugates still retained 
specificity and sensitivity to the native conformation of their protein targets. The cell lines used included 
a cell line expressing the TfR (bEnd.3), EpCAM (MDA-MB-231) and a cell line expressing neither protein 
(HEK293T). Following conjugation, TEPP-DOX displayed a moderate affinity toward the TfR (Kd=119 ± 
30.7 nM) (Figure 4.3, Table 4.1), similar to the affinity of the TEPP aptamer (Kd=110 ± 22.0 nM) while a 
decrease in affinity for EpCAM was observed (Kd=543.5 ± 340.9 nM vs Kd=85.61 ± 28.4 nM) (Figure 4.3, 
Table 4.1). This suggests that DOX intercalation may have influenced the tertiary structure of the 
aptamer, altering the single stranded binding loop which in turn altered the binding interaction between 
the aptamer and EpCAM. Given that patients with metastatic brain tumours also present with a high 
extracranial disease burden, this decrease in affinity may have a positive effect on treatment efficacy. As 
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the affinity of TEPP without DOX is higher for EpCAM, the aptamer may preferentially bind to the 
extracranial disease burden, thus limiting the bioavailability of aptamer that transcytoses into the brain. 
As the DOX intercalation reversed this binding affinity, aptamer transcytosis and drug accumulation may 
potentially be increased. This will need to be further investigated in an in vivo disease model, and if this 
issue of preferentially binding to the extracranial disease burden is still observed following the affinity 
reversal, it will need to be addressed. One possible way to overcome this limitation would be the 
implementation of a dual injection scheme, to target the extracranial disease burden first.  This would 
reduce the available number of EpCAM binding sites, leaving the bifunctional aptamer to target the TfR 
and transcytose into the brain.  This could be achieved through two sequential injections,  the first with 
the EpA aptamer that was used in the generation of the bifunctional aptamer and the second with the 
DOX-intercalated bifunctional aptamer (Macdonald et al., 2017).  Compared to TEPP-DOX, the affinity 
of TEPN-DOX towards the TfR was decreased almost 5-fold (Kd=308± 127 nM vs Kd=65.2 ± 29.9 nM). 
Similar to TEPP-DOX, DOX intercalation may have influenced the tertiary structure of the aptamer, 
altering the binding interaction between the aptamer and TfR. While a decreased affinity towards the 
TfR was observed, the aptamer still retained specificity, shown by the lack of binding to the MDA-MB-
231 cells (Kd= >10,000 nM). Interestingly, DOX intercalation had an opposite effect on the selectivity and 
sensitivity of TENP. Following DOX intercalation, TENP-DOX showed binding to TfR (Kd =303 ± 117 nM) 
but demonstrated weak binding towards EpCAM (Kd= 2274 ± 2103 nM). This suggests that DOX 
intercalation has altered or destabilised the tertiary structure of the aptamer to the point where it 
weakly binds to EpCAM but recognises and binds to the TfR with a moderate affinity.  Interestingly, a 
similar effect was observed following intercalation of DOX into TENN, with TENN-DOX demonstrating a 
low affinity towards the TfR receptor (Kd= 865 ± 439 nM). Both of these aptamers are composed of the 
same single stranded TfR binding loop derived from TfRA1 (Macdonald et al., 2016). Given that TfRA1 
binds weakly to the TfR (Kd= 2.25 ± 0.9 µM), this suggests that DOX intercalation has stabilised the 
tertiary structure of the aptamers to the point where they now bind to the TfR with moderate to low 
affinities. Similar to TENN, TENN-DOX demonstrated no binding towards the MDA-MB-231 cells (Kd= 
>10,000 nM). The intercalation of DOX into all of these aptamers had no effect on specificity for cells 
negative for EpCAM and TfR, as determined using the human cell line HEK293T (Kd= >10,000 nM). 
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Figure 4.3. Specificity of the bifunctional aptamer-DOX conjugates. TYE665 labelled DOX-
conjugated aptamers were incubated with the bEnd.3, MDA-MB-231 or HEK293T cell line and analysed 
by flow cytometry. The mean fluorescence intensity (MFI) was plotted against varying concentrations of 
EpCAM DOX loaded aptamers (0 – 400 nM) at a cell density of 5 × 105 cells/mL. Representative binding 
curves of aptamers with bEnd.3and MDA-MB-231 cells. (A) TEPP-DOX; (B) TEPN-DOX; (C) TENP-DOX; 
and (D) TENN-DOX. Data shown are mean ± SEM (n=3).  
 
Table 4.1. Binding Affinity of Bifunctional Aptamer-DOX conjugates to Transferrin Receptor 
and EpCAM 
Aptamer bEnd.3 (Kd) MDA-MB-231 (Kd) HEK293T (Kd) 
TEPP 110 ± 22.0 nM 85.6 ± 28.5 nM > 10000 nM 
TEPN 65.2 ± 29.9 nM > 10000 nM > 10000nM 
TENP > 10000nM 382.5 ± 96.7 nM > 10000 nM 
TENN > 10000nM > 10000nM > 10000nM 
TEPP-DOX 119 ± 30.7 nM 536 ± 306 nM > 10000 nM 
TEPN-DOX 308 ± 127 nM >10000 nM > 10000 nM 
TENP-DOX 303 ± 117 nM 2274 ± 2103 nM > 10000 nM 
TENN-DOX 865 ± 439 nM > 10000 nM > 10000 nM 
 
Characterisation of cellular internalisation and retention of aptamer-DOX conjugates  
Having determined the influence of DOX intercalation on specificity and selectivity of the bifunctional 
aptamers, the next step was to establish if the aptamers were internalised after binding to its cell surface 
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target. Active internalisation into the cancer cells is a vital characteristic for a cancer-targeting ligand as 
it enables the delivery and release of the cytotoxic payload inside the cells, thus bypassing the multidrug 
resistance pumps present on the cell membrane and minimising off target effects (Shigdar et al., 2011b). 
Through combining a common chemotherapeutic agent with a target-specific aptamer, drug 
internalisation occurs via receptor mediated endocytosis rather than passive diffusion or pinocytosis, 
turning an indiscriminate drug into a specific one and increasing drug accumulation (Bareford and 
Swaan, 2007). Internalisation by this method is a crucial factor in the overall design of these drug delivery 
systems as it plays a major role in drug release. For DOX to be released from the aptamer, the–NH2 
groups on DOX must be protonated (Mo et al., 2014, You et al., 2010). This reduces the hydrophobic 
interactions between the aromatic ring of DOX and the DNA bases, leading to drug release (Porciani et 
al., 2015). Through being internalised by an endocytic pathway aptamer-DOX conjugates are exposed 
to a low pH in the lysosome, resulting in drug release into the cytoplasm. The pH sensitive release of 
DOX is another major advantage of this system as it selectively increases the level of drug inside the 
cancer cell. Whereas, during circulationthe aptamer is exposed to a pH of 7.4, thus minimising non-
specific systemic toxicity.   
With the knowledge that the bifunctional aptamers are internalised intracellularly following 60 minutes 
incubation at a physiologically relevant temperature, it was imperative to establish if DOX intercalation 
affected this ability. To do this, each aptamer-DOX conjugate was prepared at an equivalent DOX 
concentration of 1 μM and incubated with MDA-MB-231 and HEK293T cells for 60 minutes and 120 
minutes, followed by visualisation using laser scanning confocal microscopy. Following 60 minutes 
incubation, TEPP-DOX and TENP-DOX bound to the cell membrane of the EpCAM positive cells (MDA-
MB-231) (Figure 4.4A, B) with minimal internalisation and DOX release observed, shown by the 
fluorescent signal of the aptamer around the perimeter of the cell. TEPN-DOX and TENN-DOX showed 
no binding or internalisation (Figure 5.4C, D).  Following an additional 60 mins incubation, TEPP-DOX and 
TENP-DOX were internalised to varying degrees into the MDA-MB-231 cells, as demonstrated by the 
red punctate pattern of intracellular distribution which is indicative of endocytosis (Figure 4.4A, B). The 
minimal fluorescent signal of DOX detected at this time point indicates that it is yet to be released from 
the aptamer, suggesting it takes longer than 120 minutes for the drug to be released. Again, TEPN-DOX 
and TENN-DOX showed no binding or internalisation (Figure 4.4C, D) (Rodman et al., 1986). The increase 
in time for TEPP-DOX to be internalised compared to TEPP suggests that drug intercalation has 
influenced internalisation rate. While this may be considered a negative influence, it is important to note 
that the intracellular TEPP-DOX signal at this time point is stronger than DOX alone (Figure 4.4E), 
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indicating that TEPP-DOX is capable of delivering a higher concentration of drug. After 60 minutes and 
120 minutes incubation, there was weak fluorescence in the HEK293T cells treated with aptamer-DOX 
conjugates or DOX. This suggests low background non-specific uptake and is consistent with what has 
been observed following the development of previous aptamer-DOX conjugates (Boyacioglu et al., 
2013, Porciani et al., 2015). Given this non-specific uptake, the propensity of the aptamer-DOX 
conjugates to bind with their target cells rather than non-target cells needed to be investigated.  
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Figure 4.4. Internalisation of bifunctional aptamer-DOX conjugates. Each bifunctional aptamer-
DOX conjugate was incubated with EpCAM positive (MDA-MB-231) and negative (HEK293T) cell lines at 
an equivalent DOX concentration of 1 μM for 60 min and 120 min at 37 °C, followed by visualisation 
using laser scanning confocal microscopy. Representative images of TEPP-DOX (A); TEPN-DOX (B); TENP-
DOX (C); and TENN-DOX (D). Free DOX (E) at a concentration of 1 μM was incubated with EpCAM 
positive (MDA-MB-231) and negative (HEK293T) cell lines for 60 min and 120 min at 37 °C. Scale bar: 10 
μm. (n=3). 
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To assess drug retention, TEPP-DOX and DOX were incubated with MDA-MB-231 cells for 120 mins then 
thoroughly washed and incubated with fresh media for a further 24 h. Following this period, DOX 
retained in the cells treated with TEPP-DOX (Figure 4.5A) was clearly detectable whereas only residual 
DOX fluorescence was observed in the cells treated with DOX alone (Figure 4.5A). Following 
quantification using ImageJ, it was established that the DOX fluorescent signal for TEPP-DOX was 
significantly higher than that of DOX (p<0.05) (Figure 4.5B) at 24 hours, indicating superior drug 
retention. This can be attributed to the fact that TEPP-DOX is most likely internalised via receptor 
mediated endocytosis whereas DOX is internalised via diffusion, making it highly susceptible to drug 
efflux. Overall, this data suggests that bifunctional aptamer-DOX resulted in a more effective 
accumulation of DOX in MDA-MB-231 cells compared to DOX alone. 
 
 
Figure 4.5. Retention of bifunctional aptamer-DOX conjugates. To investigate drug retention, 
following 120 min incubation with TEPP-DOX and DOX, EpCAM positive (MDA-MB-231) cells were 
washed and incubated for a further 24 h in fresh medium. (A) Representative images of TEPP-DOX and 
DOX at 24 h (B) Quantification analysis of DOX retention at 24 h. Red: bifunctional aptamer; green: DOX; 
blue: nuclear stain. CTCF: corrected total cell fluorescence. Scale bar: 10 μm. (n=3). 
 
Determination of aptamer-DOX conjugate permeability across an in vitro mouse 
blood−brain barrier model  
In order for the bifunctional aptamer-DOX conjugates to be successfully applied to targeting brain 
metastases, they must ﬁrst be able to cross the BBB. To assess if the aptamers maintained this ability 
subsequent to drug intercalation, an in vitro model of this physiological system was used as a proof of 
concept. However, creating an aptamer which is capable of crossing the BBB is only the first step in 
targeting brain metastases, the aptamer must also be able to target a specific cell population within the 
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brain. To investigate the ability of the aptamers to not only traverse through an endothelial monolayer 
but to retain functionality and specifically target EpCAM positive TNBC cells, MDA-MB-231 cells were 
seeded in the abluminal compartment of the in vitro BBB model alongside cells devoid of EpCAM 
expression (HEK293T) at a ratio of 1:1. Each aptamer-DOX conjugate was prepared at an equivalent DOX 
concentration of 1 μM, added to the luminal compartment and incubated with the in vitro system for 
three hours, followed by visualisation using laser scanning confocal microscopy. Consistent with our 
previous findings using the TEPP aptamer, TEPP-DOX was able to transcytose through the endothelial 
monolayer and specifically targeted only the MDA-MB-231 cells, as shown in Figure 5.6A. Theoretically, 
while TEPN-DOX is capable of transcytosing the BBB (bEnd.3 Kd= 307.6 ± 126.7 nM), upon entering the 
abluminal compartment it would not have the ability to target and be internalised into any cells. 
Consistent with the TEPN aptamer, this was observed for TEPN-DOX, with both cell lines demonstrating 
no sign of internalisation (Figure 4.6A), further supporting the highly selective ability of the bifunctional 
aptamer. Interestingly, both TENN-DOX and TENP-DOX showed minimal internalisation into the MDA-
MB-231 cells and no sign of internalisation in the HEK293T cell line (Figure 4.6A). Given that following 
DOX intercalation both of these aptamers demonstrated moderate to low affinities to the TfR receptor, 
it was anticipated that they may possess the ability to transcytose the BBB. As some internalisation of 
TENP-DOX was observed in previous experiments (Figure 4.4C) the minimal internalisation observed in 
the MDA-MB-231 cells was not surprising. However, given the lack of sensitivity of TENN-DOX toward 
EpCAM (Kd= >10000 nM), it was not expected that it would be internalised into the MDA-MB-231 cell 
line. Compared to TEPP-DOX which demonstrated a high aptamer accumulation in the MDA-MB-231 
cell line, TENN-DOX showed little accumulation (Figure 5.6A). This is suggestive of a slower endocytosis 
profile or that the aptamer is possibly being taken up by micropinocytosis a non-specific uptake 
mechanism, similar to the nucleolin aptamer (Reyes-Reyes et al., 2015). These results demonstrate that 
the TEPP-DOX conjugate is capable of crossing the BBB in vitro  and of exclusively targeting EpCAM 
expressing TNBC cells. While the in vitro BBB model serves as a suitable tool for assessing BBB 
permeability, it still has limitations, with the main being its simplistic nature. In an in vivo system, the BBB 
is composed of and regulated by an intricate balance of a variety of cell types. This complexity is not 
replicated in an in vitro model and is therefore a major limitation. Resulting from this, the next step in 
the development of this bifunctional aptamer-DOX conjugate will be to investigate its ability to 
penetrate the BBB in vivo and specifically deliver DOX to EpCAM positive TNBC brain metastases.   
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Figure 4.6. Internalisation of bifunctional aptamer-DOX conjugate with a mouse in vitro BBB model. 
Each bifunctional aptamer-DOX conjugate was incubated with the in vitro BBB for 240 min at 37°C, prior 
to trypsinization and visualisation using laser scanning confocal microscopy. An anti-EpCAM antibody 
was used to differentiate EpCAM positive MDA-MB-231 cells. Data are representative of three 
independent experiments Yellow: antibody; red: bifunctional aptamer; green: DOX; blue: nuclear stain. 
Scale bar: 10 μm. (n=3). 
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Conclusion 
This study has shown that the intercalation of a common chemotherapeutic into a bifunctional aptamer 
generated a drug delivery vehicle which is capable of transcytosing an in vitro BBB model and specifically 
delivering its payload. While previous studies have generated drug delivery vehicles utilising mono-
functional aptamers, this is the first study to explore the use of a bifunctional aptamer. From previous 
studies utilising therapeutic antibodies targeting the TfR, it was discovered that a lower binding affinity 
was more favourable than a higher affinity antibody for maximal brain uptake, with the highest uptake 
observed utilising an antibody with a binding affinity of 111 ± 16 nM (Yu et al., 2011). In this study, we 
have shown that intercalating DOX into the TEPP aptamer generated a drug delivery vehicle with a 
moderate affinity (110 ± 16 nM 22.0 nM) which is capable of transcytosing the BBB in vitro and 
specifically target EpCAM positive TNBC cells. Through this simple drug intercalation, we have developed 
a system which we hypothesise will transcytose the BBB in vivo and specifically deliver cytotoxic 
payloads to TNBC brain metastases. This bifunctional aptamer drug conjugate system is currently being 
investigated further as a novel therapeutic for TNBC brain metastases. 
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Chapter 5:  Conclusion and future directions 
 
Conclusions  
Despite advances in diagnosis and treatment over the past few decades, the survival rates for patients 
suffering from brain metastases is poor, with few patients living longer than a year. This poor prognosis 
can largely be attributed to the location of these tumours. Situated in the safe sanctuary of the brain, 
treatment options are limited given the restrictive nature of the BBB. A novel approach emerging to 
overcome this barrier is to target receptor mediated transport mechanisms present on the endothelial 
cell membranes. Whilst these transport systems allow the barrier to be overcome, upon the transported 
drug entering the brain microenvironment a second problem arises in non-specific delivery. The 
research presented in this Thesis reports the development of a bifunctional aptamer drug conjugate 
which is capable of traversing the BBB in vitro and delivering an impenetrable drug to a specific cell 
population.  
Given the strong expression of the TfR on the BBB, it is a highly attractive target and as a result, 
antibodies against this receptor have been generated in an attempt to improve the therapeutic 
treatment of Alzheimer’s disease and glioblastoma (Xu et al., 2011, Wilner et al., 2012, Yu et al., 2011). 
Studies with these antibodies have demonstrated that a therapeutically relevant concentration can be 
delivered across the BBB in an in vivo model. However, antibodies carry some immunological risk as well 
as other severe side effects, and a novel therapeutic strategy with fewer side effects is required (Weiner, 
2015, Yu et al., 2011).  Given the numerous advantages aptamers have over antibodies, they are highly 
attractive alternatives. Recently, Chen et al. reported the development of DNA and RNA aptamers which 
selectively recognises the extracellular domain of the mouse TfR (Chen et al., 2008). Originally 64 
nucleotides long, Chen and colleagues truncated the selected DNA aptamer, GS24, to 50 nucleotides 
while still maintaining sensitivity and selectivity (Chen et al., 2008). While demonstrating attractive 
binding properties for therapeutic application, the large size of this aptamer limits its therapeutic 
capabilities. The first aim of this Thesis was to truncate the GS24 transferrin receptor aptamer to its 
shortest functional length while maintaining specificity and selectivity. Given that both the full length 
aptamer and the truncated version possessed an identical loop region, it was postulated that this region 
was the primary binding site. To test this, the aptamer was truncated, mutations were introduced into 
the binding loop to modulate binding affinity and the resulting aptamers characterised (Chapter 3). 
Through this, an aptamer with a moderate affinity to the TfR was developed, an attribute required for 
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efficient transcytosis as previously demonstrated. The observation that this aptamer colocalised with 
the transferrin receptor antibody, suggests that it could be used for therapeutic delivery across the BBB. 
While this aptamer could be capable of transcytosing the BBB, once in the brain, it would freely diffuse 
and potentially cause neurotoxicity. Therefore, Chapter 3 of this Thesis aimed to further functionalise 
this aptamer by combining it with an aptamer targeting an overexpressed biomarker on TNBC cells, to 
direct the aptamer to a specific population of cells once in the brain.   
Given its overexpression on the tumourigenic population compared to normal epithelial tissue, EpCAM 
is a highly attractive therapeutic target for TNBC brain metastases. Following the success of truncating 
the GS24 aptamer, the effect of truncating the 48 nucleotide SYL3C DNA EpCAM aptamer was 
investigated (Chapter 3 Supplementary). Based upon the 2D structure, the aptamer was truncated to 
generate three significantly shorter aptamers suitable for fusion with the TfR aptamer. Subsequent to 
characterisation using flow cytometry and confocal microscopy, it was determined that EpA was the 
most suitable candidate to be fused with the TfR aptamer given its moderate affinity towards both high 
and low EpCAM expressing cells and superior cellular internalisation. Through the fusion of the two 
truncated aptamer sequences, a 34 nucleotide bifunctional aptamer was generated. After confirming 
the sensitivity and selectivity of the aptamer toward the TfR and EpCAM, the ability of this aptamer to 
transcytose the BBB and target the EpCAM positive TNBC was assessed. Following transcytosis 
confirmation of using an in vitro model, the ability of this aptamer to transcytose the BBB was then 
confirmed in a healthy in vivo model, where 0.2% of the injected dose was measured within the brain 
thirty minutes after administration. Compared to other studies targeting brain disorders, this 
percentage of injected dose can be considered low, with some studies reporting a similar percentage 
two hours post administration and some reporting as high as one percent 24 hours post administration 
(Ke et al., 2009, Jensen et al., 2013). However, an important factor to consider when comparing these 
results is the fact that the biodistriubtion experiment undertaken in this study was conducted in a 
healthy in vivo model. Consequently, this means that upon the aptamer transcytosing the BBB, it lacked 
the second target, EpCAM.  This means that accumulation within the brain is not representative of what 
might be seen in a metastatic model the aptamer is most likely transcytosing back through the BBB and 
re-entering systemic circulation within a short length of time. Compared to antibody therapies targeting 
the TfR, this system has the advantage of targeting a specific population upon entering the brain in 
addition to being significantly smaller in size and lacking an immunogenic response. To date, this is the 
first bifunctional aptamer synthesised in this manner, where the binding of the TfR aptamer influences 
the binding of the EpCAM aptamer.  While this aptamer serves as a proof of concept for targeting TNBC 
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brain metastases, alone it lacks therapeutic effect and therefore needs to be further functionalised in 
order to be employed for the treatment of these metastatic tumours.  
The specific targeting ability of aptamers, combined with their quick uptake and tumour penetration 
ability make them an excellent platform for the delivery of cytotoxic agents. Previously mentioned, the 
vast majority of chemotherapeutic agents employed in the treatment of TNBC brain metastases are 
incapable of crossing the BBB. For the small proportion which are capable, their efficacy is further 
complicated by their dominating non-specific interactions, and the development of acquired 
chemoresistance. DOX is one of the most widely used chemotherapeutic agents employed for the 
treatment of a number of cancers, including TNBC. Alone, DOX exhibits poor penetration of the BBB. 
This is largely the result of its small size in combination with the presence of drug efflux transporters on 
the BBB.  As the cytotoxic effect of DOX entails intercalating into double stranded DNA and disrupting 
replication and transcription, it can easily be intercalated into the double stranded aptamer stem region. 
Through this, DOX is specifically internalised into the target cell via endocytosis, thus eliminating the non-
specific side effects and increasing the intracellular concentration as the drug efflux pumps are bypassed.   
Using the bifunctional aptamer develop in Chapter 3, in Chapter 4 of this Thesis, DOX was intercalated 
into the aptamer to provide a therapeutic effect. Subsequent to DOX intercalation, the sensitivity and 
specificity of the aptamer-drug conjugates was characterised to investigate the effect of drug 
intercalation. Though DOX intercalation marginally affected the aptamers affinity towards the TfR, its 
affinity towards to EpCAM was decreased by almost 6-fold. While this difference was observed, it 
appeared to have no effect on the aptamers ability to be intracellularly internalised. Of most importance 
in this chapter, was the influence drug intercalation had on the aptamers ability to transcytose the BBB. 
Using an in vitro BBB model, it was confirmed that drug intercalation did not influence the functionality 
of the aptamer with the fluorescent signals generated by the aptamer and DOX clearly detectable in the 
EpCAM positive cells following a three-hour incubation and almost undetectable in the EpCAM negative 
cells.  
In conclusion, within this Thesis it has been shown that through the truncation and fusion of two 
aptamer sequences, and a bifunctional aptamer can be generated which is capable of transcytosing the 
BBB and targeting a specific cell population within the brain. Further development of the drug-loaded 
aptamer will facilitate the improvement of specific treatments for TNBC brain metastases and 
potentially improve patient quality of life and median survival time.  
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Future Directions 
Within this Thesis the development of a bifunctional aptamer DOX conjugate has been developed for 
the specific treatment of EpCAM positive TNBC brain metastases. The experimental results thus far 
show great promise for this therapeutic modality; however, a significant amount of experimental work 
is still required before it is suitable for entering the clinical setting. This work includes determining the 
ability of the bifunctional aptamer DOX conjugate to traverse the BBB in vivo, evaluating its ability to 
reduce tumourigenic potential, prolong survival and determining cross reactivity between mouse and 
human TfR.  
In this Thesis, the ability of the bifunctional aptamer DOX conjugate to transcytose the BBB has been 
confirmed in vitro but has not been investigated in vivo. While during the metastatic cascade the BBB is 
initially broken down, during treatment it begins to repair itself, trapping the remaining potentially 
chemo-resistant tumour cells within the brain, thus limiting treatment options and increasing the risk of 
tumour recurrence. Initially this disruption would allow the bifunctional aptamer DOX conjugate to gain 
access to the metastatic tumours, however following the barrier being repaired, it is essential the 
conjugate system is capable of transcytosing a healthy intact BBB. This ability could be investigated in a 
manner similar to the biodistriubtion study undertaken in Chapter 3, whereby healthy mice received a 
single intravenous injection and aptamer concentration within the brain was measured. Upon 
confirmation that the bifunctional aptamer DOX conjugate is capable of transcytosing the BBB, its ability 
to reduce tumourigenic potential would need to be investigated.  
The bifunctional aptamer system in this Thesis is designed to target EpCAM following transcytosis into 
the brain. Discussed previously, this biomarker is overexpressed on the non-tumourigenic population 
and the tumourigenic population, CSCs. The experimental work completed in Chapter 3 and Chapter 4 
of this Thesis established the ability of the bifunctional aptamer alone and the DOX conjugated aptamer 
to specifically target EpCAM expressing cells. However, none established the ability of the aptamer to 
target the CSCs and reduce tumourigenic potential. This ability would need to initially be assessed in 
vitro through limiting dilution assays prior to being investigated using an ex vivo limiting dilution assay. 
While these experiments would demonstrate the ability of the bifunctional aptamer DOX conjugate to 
reduce tumourigenic potential, they do not demonstrate its ability to prolong survival.  
The main goal in the development of this aptamer drug system is to inhibit tumour progression and 
prolong patient survival and improve quality of life. In order to evaluate the efficacy of the bifunctional 
aptamer DOX system to achieve this, a preclinical metastatic xenograft model will need to be employed. 
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Mice would be inoculated and metastatic tumours allowed to establish prior to treatment with the 
bifunctional aptamer DOX system. This would confirm if conjugating the DOX increases the 
concentration of drug in the brain metastases and mitigates the cytotoxic side effects associated with 
chemotherapeutic treatment. Furthermore, using this model would give a realistic representation of the 
patient setting, with both metastatic lesions and extracranial disease burden present, allowing the 
binding propensity of the aptamer to target the TfR on the BBB or EpCAM on the extracranial disease to 
be investigated. 
All of the experimental work thus far has been completed using mouse brain endothelial cells (bEnd.3). 
This is because the TfR portion of the aptamer binds to mouse TfR. Therefore, moving forward for the 
treatment of TNBC brain metastases cross reactivity of the bifunctional aptamer needs to be 
determined. This would involve determining the binding affinity of the aptamer against human brain 
endothelial cells. If the aptamer is found to be cross reactive between the two species, the transition 
from bench to clinical trials will be a lot smoother. However, if it is not cross reactive, a new aptamer 
targeting both the human TfR and mouse TfR will be required. This can be achieved through the 
generation of an aptamer using Toggle SELEX, a type of SELEX with modified selection conditions 
compared to the characterised protocol. Within this selection process, different targets are ‘toggled’ 
between the varying rounds of selection, to produce a cross-reactive aptamer. Following the generation 
of the cross-reactive bifunctional aptamer it would then be subjected to the same characterisation as 
TfRA4 and EpA in Chapter 2 prior to fusion with the EpA aptamer to generate a bi-specific bifunctional 
aptamer.  
As a result of the diverse range of applications aptamers can be employed in, the bifunctional, TfR and 
EpCAM aptamers generated in this Thesis can be functionalised for a number of other applications.  As 
they have no therapeutic effect, they are highly suitable for development for diagnostic application. The 
chemical synthesis of aptamers allows modifications to be easily introduced at the 5’ end or 3’ end of 
their structure through phosphoramidite chemistry, including the attachment of fluorophores, 
magnetic resonance imaging (MRI) contrast agents and radioisotopes, making them suitable imaging 
probes  (Wu et al., 2015).  Subsequent to modification with a chelator moiety, such as DOTA or NOTA, 
the bifunctional aptamer could then be radiolabelled using 99mTc, which has previously been used to 
radiolabel an aptamer targeting tenascin-C (Hicke et al., 2006). Following subcutaneous injection, the 
radiolabelled aptamer was rapidly taken up into the tumour cells and demonstrated deep tumour 
penetration and rapid clearance from the bloodstream, all highly desirable characteristics for an imaging 
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probe (Hicke et al., 2006). The ease by which aptamers can be modified additionally allows for them to 
be functionalised by methods other than direct drug conjugation to have a therapeutic effect.  
Given their high loading drug capacity, over the past decade nanoparticles have been developed as drug 
delivery vehicles (Orilall and Wiesner, 2011). While, alone, these vehicles lack specific targeting, once 
combined with an active targeting mechanism, such as aptamers, highly specific drug delivery vehicles 
are developed. Through encapsulating cytotoxic agents which alone are incapable of traversing the BBB, 
and conjugating them with the bifunctional aptamer, a wider range of therapeutics could be employed 
for the treatment of TNBC brain metastases. As an example, although Paclitaxel is highly lipophilic, drug 
concentration in the brain is considerably low following intravenous injection (Eiseman et al., 1994, 
Heimans et al., 1994).  This is likely due to high expression levels of MDR1 on the luminal surface of the 
BBB. The encapsulation of Paclitaxel in PLGA-PEG nanoparticles has previously been reported (Guo et 
al., 2011). Through functionalising these nanoparticles with the bifunctional aptamer, drug 
concentration within the brain could be increased following the nanoparticles crossing the BBB via 
transcytosis, thus avoiding the efflux pumps present on the barrier. While this example involved 
encapsulating a lipid soluble drug which is capable of traversing the BBB, this method could also be 
employed to encapsulate lipid insoluble drugs and water insoluble drugs, such as docetaxel. This delivery 
system could also be employed to deliver siRNAs or antisense oligonucleotides targeting proteins 
associated with multidrug resistance. Through this a dual targeting treatment, a regimen could be 
developed to firstly inhibit the proteins associated with multidrug resistance, which could then influence 
the efficacy of the cytotoxic agent delivered in the second system. This treatment strategy could then 
further be enhanced through combining the nanoparticle system with the bifunctional aptamer DOX 
conjugate to deliver a cocktail of chemotherapeutics to the highly aggressive TNBC brain metastases.  
While this Thesis focused solely on the therapeutic potential of the bifunctional aptamer, the aptamers 
used in its development could be developed for application in cancer therapy. Given the overexpression 
of EpCAM and the TfR on a number of solid cancers, they could be applied in a similar manner to those 
discussed for the bifunctional aptamer for the treatment and diagnosis of extracranial tumours. 
Furthermore, the results from this study serve as a proof of concept for the development of targeted 
delivery vehicles for other brain disorders, such as a primary brain tumours or Alzheimer’s disease, as 
theoretically the EpCAM portion is interchangeable allowing it to be swapped for aptamers targeting 
biomarkers associated with the brain disorders.  
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Chapter 6: Appendix 
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